PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
15213856-8	2004	Conversely, over-expression of active PI 3-K and pharmacological inhibiton of Src with PP2 and CGP77675, enhanced basal and manganese-induced alpha V beta 3 clustering.	Manganese	124-133	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	87-90
15240725-7	2004	This activation in EDTA resulted in CD11b, CD35 and CD66 up-regulation and in an oxidative response, all blocked by SB203580 and PP2.	Edetic Acid	19-23	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	129-132
15107421-4	2004	Pretreatment with the specific Src inhibitor PP2, or expression of dominant-negative, kinase-dead c-Src abrogates EphB1-induced tyrosine phosphorylation of paxillin.	Tyrosine	128-136	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	45-48
14604860-8	2004	PP2 inhibited p130(Cas) tyrosine phosphorylation, but dominant-negative p130(Cas) did not inhibit cell spreading.	Tyrosine	24-32	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
14749212-7	2004	In addition, adenoviral overexpression of dominant-negative ras (Ad.HA-Ras(N17)) partially inhibited the ATP- and PDBu-induced activation of ERK1/2 and blocked ionomycin- and EGF-stimulated ERK1/2, and inhibition of tyrosine kinases with AG-1478, an EGFR inhibitor, or the src family kinase inhibitor PP2 attenuated ATP-stimulated ERK1/2 activation.	Adenosine Triphosphate	105-108	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	301-304
15110780-5	2004	The acinar cell phospholipid secretory responses to isoproterenol, moreover, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR phosphorylation.	Phospholipids	16-28	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	95-98
15110780-5	2004	The acinar cell phospholipid secretory responses to isoproterenol, moreover, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR phosphorylation.	Isoproterenol	52-65	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	95-98
15010462-4	2004	Conversely, inhibition of Src family tyrosine kinases by the pyrazolopyrimidine PP2, as in kinase-inactive Hck mutants, significantly reduces IL-6-triggered activation of extracellular signal-regulated kinase and AKT-1, leading to significant reduction of multiple myeloma cell proliferation and survival.	1H-pyrazolo[4,3-d]pyrimidine	61-79	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	80-83
14761972-8	2004	This epidermal growth factor-induced tyrosine phosphorylation of TRPC6 was significantly blocked by PP2, a specific inhibitor of Src family PTKs, and by a dominant negative form of Fyn, suggesting that the direct phosphorylation of TRPC6 by Src family PTKs could be caused by physiological stimulation.	Tyrosine	37-45	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	100-103
14978237-2	2004	The Tyr701 phosphorylation of signal transducer and activator of transcription 1 (STAT1) induced by interferon-gamma (IFN-gamma) and 12-O-tetradecanoylphorbol 13-acetate (TPA) was inhibited by the protein kinase C (PKC) inhibitor staurosporine, the tyrosine kinase inhibitor herbimycin, or the Src kinase inhibitor PP2.	13-acetate	159-169	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	315-318
15024039-9	2004	Furthermore, the selective Src-family PTK inhibitor PP2 (5 microM) stimulated I(Cl.vol), mimicking genistein, whereas the selective EGFR (ErbB-1) kinase inhibitor tyrphostin B56 (AG 556, 25 microM) reduced I(Cl.vol), mimicking A23 and A25.	Genistein	99-108	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	52-55
15024039-10	2004	The effects of both PP2 and B56 also were substantially antagonized by pretreatment with VO(4)(-3).	vo(4)	89-94	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	20-23
14679211-3	2004	Using whole cell recordings, we found that inhibition of SFK tyrosine kinase activity by PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo(3,4-d)pyrimidine) treatment or expression of a kinase-defective c-Src reduced the peak amplitude of nicotine-induced currents in chromaffin cells or in human embryonic kidney cells ectopically expressing functional neuronal alpha3beta4alpha5 acetylcholine receptors (AChRs).	4-amino-5-(4-chlorophenyl)-	94-121	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	89-92
14679211-3	2004	Using whole cell recordings, we found that inhibition of SFK tyrosine kinase activity by PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo(3,4-d)pyrimidine) treatment or expression of a kinase-defective c-Src reduced the peak amplitude of nicotine-induced currents in chromaffin cells or in human embryonic kidney cells ectopically expressing functional neuronal alpha3beta4alpha5 acetylcholine receptors (AChRs).	Nicotine	241-249	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	89-92
14679211-3	2004	Using whole cell recordings, we found that inhibition of SFK tyrosine kinase activity by PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo(3,4-d)pyrimidine) treatment or expression of a kinase-defective c-Src reduced the peak amplitude of nicotine-induced currents in chromaffin cells or in human embryonic kidney cells ectopically expressing functional neuronal alpha3beta4alpha5 acetylcholine receptors (AChRs).	chromaffin	270-280	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	89-92
15006901-10	2004	Inhibition of adhesion- and cytokine-induced O(2)(-) release by 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazol[3,4-d]pyrimidine (PP2) indicated that a Src-family tyrosine kinase was the principal regulatory pathway mediating this response in neutrophils, a distal role for p38 MAPK was revealed by use of SB203580.	4-amino-5-(4-chlorophenyl	64-89	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	128-131
15006901-10	2004	Inhibition of adhesion- and cytokine-induced O(2)(-) release by 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazol[3,4-d]pyrimidine (PP2) indicated that a Src-family tyrosine kinase was the principal regulatory pathway mediating this response in neutrophils, a distal role for p38 MAPK was revealed by use of SB203580.	pyrazol[3,4-d]pyrimidine	102-126	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	128-131
15006901-12	2004	Tyrosine phosphorylation of c-Fgr, a Src-family tyrosine kinase, occurred following ACLB adhesion and exposure to TNF alpha, and was susceptible to inhibition by PP2.	Tyrosine	0-8	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	162-165
15073106-11	2004	PP2 enhanced inherent gemcitabine chemosensitivity and attenuated gemcitabine resistance in PANC1(GemRes).	gemcitabine	22-33	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
15073106-11	2004	PP2 enhanced inherent gemcitabine chemosensitivity and attenuated gemcitabine resistance in PANC1(GemRes).	gemcitabine	66-77	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
15073106-13	2004	PP2 augmented gemcitabine-induced caspase-mediated apoptosis, suppressed RRM2 expression, and decreased activity of the RRM2-regulating transcription factor E2F1 in PANC1(GemRes).	gemcitabine	14-25	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
14978237-2	2004	The Tyr701 phosphorylation of signal transducer and activator of transcription 1 (STAT1) induced by interferon-gamma (IFN-gamma) and 12-O-tetradecanoylphorbol 13-acetate (TPA) was inhibited by the protein kinase C (PKC) inhibitor staurosporine, the tyrosine kinase inhibitor herbimycin, or the Src kinase inhibitor PP2.	Tetradecanoylphorbol Acetate	171-174	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	315-318
14660564-5	2004	The complexes with the S-adenosyl-l-methionine methyl donor and the S-adenosyl-l-homocysteine product and inhibitor unambiguously revealed the co-substrate binding site and provided a convincing hypothesis for the PP2A C-terminal peptide binding site.	S-Adenosylmethionine	23-46	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	214-217
14660564-5	2004	The complexes with the S-adenosyl-l-methionine methyl donor and the S-adenosyl-l-homocysteine product and inhibitor unambiguously revealed the co-substrate binding site and provided a convincing hypothesis for the PP2A C-terminal peptide binding site.	Sulfur	23-24	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	214-217
14670955-5	2004	Dual immunofluorescence labeling of the P2Y(2) receptor and the EGFR indicated that UTP caused an increase in the co-localization of these receptors in the plasma membrane that was prevented by the Src inhibitor PP2.	Uridine Triphosphate	84-87	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	212-215
14660564-5	2004	The complexes with the S-adenosyl-l-methionine methyl donor and the S-adenosyl-l-homocysteine product and inhibitor unambiguously revealed the co-substrate binding site and provided a convincing hypothesis for the PP2A C-terminal peptide binding site.	S-Adenosylhomocysteine	70-93	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	214-217
14741711-5	2004	Furthermore, PP2, a specific inhibitor of Src-family tyrosine kinases (PTKs), was found to inhibit both pervanadate-induced reverse translocation and tyrosine phosphorylation of PMA-stimulated PKCbetaII, suggesting that these two pervanadate-induced responses are mediated by Src-family PTKs.	pervanadate	104-115	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	13-16
14977859-3	2004	In the current study, we determined the ability of PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), a Src kinase inhibitor, to reduce u-PAR expression and colon cancer invasion.	AG 1879	56-119	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	51-54
14741711-5	2004	Furthermore, PP2, a specific inhibitor of Src-family tyrosine kinases (PTKs), was found to inhibit both pervanadate-induced reverse translocation and tyrosine phosphorylation of PMA-stimulated PKCbetaII, suggesting that these two pervanadate-induced responses are mediated by Src-family PTKs.	Tyrosine	53-61	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	13-16
14741711-5	2004	Furthermore, PP2, a specific inhibitor of Src-family tyrosine kinases (PTKs), was found to inhibit both pervanadate-induced reverse translocation and tyrosine phosphorylation of PMA-stimulated PKCbetaII, suggesting that these two pervanadate-induced responses are mediated by Src-family PTKs.	Tetradecanoylphorbol Acetate	178-181	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	13-16
14741711-5	2004	Furthermore, PP2, a specific inhibitor of Src-family tyrosine kinases (PTKs), was found to inhibit both pervanadate-induced reverse translocation and tyrosine phosphorylation of PMA-stimulated PKCbetaII, suggesting that these two pervanadate-induced responses are mediated by Src-family PTKs.	pervanadate	230-241	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	13-16
15527548-5	2004	The acinar cell secretory responses to isoproterenol, furthermore, were blunted in a concentration-dependent fashion by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation.	Isoproterenol	39-52	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	120-123
15674841-9	2004	The TCDD-induced activation of c-Src could be blocked by pretreated MCF10A cells with antisense oligonucleotides against c-src or with a specific inhibitor of Src kinase, PP-2.	Polychlorinated Dibenzodioxins	4-8	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	171-175
15674848-5	2004	To test the hypothesis that TCDD-induced c-Src kinase activation is casually related to this compound"s antagonistic action against insulin, we treated MCF10A cells with two c-Src blocking agents, an anti-Src antisense oligonucleotides blocker and a known specific inhibitor of c-Src kinase, PP-2 and studied the effect of insulin and TCDD on cell proliferation.	Polychlorinated Dibenzodioxins	28-32	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	292-296
14750954-4	2003	The phosphorylation of Tyr 845 can be inhibited by PP2, but not by AG1478, and is associated with Src activation and Stat 3/5 phosphorylation, but not with MAP (mitogen-activated protein) kinase phosphorylation.	Tyrosine	23-26	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	51-54
14656986-7	2003	However, PP2 failed to alter thrombin-induced morphological changes and exhibited only partial inhibition of FAK site-specific tyrosine phosphorylation.	Tyrosine	127-135	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	9-12
14504278-8	2003	Activation of SRC tyrosine kinases was accompanied by tyrosine phosphorylation of ezrin at Tyr-146, which was inhibited by PP2, an SRC tyrosine kinase inhibitor.	Tyrosine	18-26	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	123-126
14504278-8	2003	Activation of SRC tyrosine kinases was accompanied by tyrosine phosphorylation of ezrin at Tyr-146, which was inhibited by PP2, an SRC tyrosine kinase inhibitor.	Tyrosine	91-94	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	123-126
12907686-7	2003	Furthermore, the increased Cx43 tyrosine phosphorylation was correlated with ET-1-induced increase of c-Src activity, and PP2 suppressed the ET-1-induced Cx43 tyrosine phosphorylation, indicating that inhibition of Cx43-based GJIC is mainly mediated by the Src tyrosine kinase pathway.	Tyrosine	159-167	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	122-125
12682076-8	2003	On the contrary, PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazole[3,4-d]pyrimidine), an inhibitor of Src kinase, completely prevents DEM- and H2O2-induced AKT activation but has no effect on the pathway of ERKs.	4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazole[3,4-d]pyrimidine	22-85	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	17-20
12893742-7	2003	Furthermore, Src kinases are involved in flow-stimulated VEGFR2 because inhibiting Src kinases by PP2, a selective inhibitor for Src kinases, abolishes flow-induced VEGFR2 tyrosine phosphorylation and downstream signaling.	Tyrosine	172-180	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	98-101
12869350-5	2003	PP2, although having no effect on RGD peptide-binding to CRP, completely blocked aggregation and tyrosine phosphorylation of Syk and phospholipase Cgamma2 (PLCgamma2).	Tyrosine	97-105	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
12682076-8	2003	On the contrary, PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazole[3,4-d]pyrimidine), an inhibitor of Src kinase, completely prevents DEM- and H2O2-induced AKT activation but has no effect on the pathway of ERKs.	diethyl maleate	136-139	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	17-20
12682076-8	2003	On the contrary, PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazole[3,4-d]pyrimidine), an inhibitor of Src kinase, completely prevents DEM- and H2O2-induced AKT activation but has no effect on the pathway of ERKs.	Hydrogen Peroxide	145-149	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	17-20
12522014-6	2003	HMVECs pretreated with the Src inhibitor (PP2) and the PI3K inhibitor (LY294002) or transfected with Src antisense oligonucleotides or Akt dominant-negative mutants significantly inhibited sE-selectin-mediated HMVEC tube formation.	Oligonucleotides	115-131	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	42-45
12790800-7	2003	PP2 treatment inhibited basal cortisol production while significantly increasing the production of DHEA and DHEA-S (together referred to as DHEA(S)) in both adrenal cell models.	Dehydroepiandrosterone	99-103	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
12790800-7	2003	PP2 treatment inhibited basal cortisol production while significantly increasing the production of DHEA and DHEA-S (together referred to as DHEA(S)) in both adrenal cell models.	Dehydroepiandrosterone	108-114	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
12790800-9	2003	Treatment with PP2 also increased mRNA levels for StAR, and cholesterol side-chain cleavage (CYP11A) and 17alpha-hydroxylase/17,20-lyase (CYP17) enzymes.	Cholesterol	60-71	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	15-18
12790800-11	2003	However, treatment of adrenal cells with a combination of PP2 and dbcAMP enhanced the production of DHEA(S) while inhibiting cortisol production.	Hydrocortisone	125-133	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	58-61
12790800-12	2003	During dbcAMP treatment PP2 was able to augment the expression of CYP17 and to inhibit the induction of 3beta-hydroxysteroid dehydrogenase type 2 (HSD3B2) levels.	Bucladesine	7-13	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	24-27
12767803-8	2003	Chk (no inhibition up to 18.5 microM) and Csk (IC(50)= 1 microM) were differentially inhibited by PP2, probably due to the size difference of one residue (Thr265 in Csk versus Met304 in Chk) in the ATP-binding domain.	Adenosine Triphosphate	198-201	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	98-101
12522014-8	2003	Similarly, in the Matrigel-plug in vivo assay, sE-selectin induced a 2.2-fold increase in blood vessel formation, which was significantly inhibited by PP2 and LY294002 but not by PD98059.	se-selectin	47-58	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	151-154
12645577-2	2003	TNF-alpha- or 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ICAM-1 promoter activity was inhibited by a protein kinase C (PKC) inhibitor (staurosporine), tyrosine kinase inhibitors (genistein and herbimycin A), or an Src-specific tyrosine kinase inhibitor (PP2).	Tetradecanoylphorbol Acetate	14-50	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	262-265
12756358-10	2003	The cell death response precipitated by expanded polytetrafluoroethylene, Dacron, or the roughened surfaces was significantly reduced with treatment of the neutrophils with catalase, diphenylene iodonium, or the src kinase inhibitor PP2 before adhesion.	Polytetrafluoroethylene	49-72	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	233-236
12756358-10	2003	The cell death response precipitated by expanded polytetrafluoroethylene, Dacron, or the roughened surfaces was significantly reduced with treatment of the neutrophils with catalase, diphenylene iodonium, or the src kinase inhibitor PP2 before adhesion.	Polyethylene Terephthalates	74-80	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	233-236
12756358-10	2003	The cell death response precipitated by expanded polytetrafluoroethylene, Dacron, or the roughened surfaces was significantly reduced with treatment of the neutrophils with catalase, diphenylene iodonium, or the src kinase inhibitor PP2 before adhesion.	diphenyleneiodonium	183-203	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	233-236
12739161-6	2003	Deoxygenation or 4-amino-5-(4-chlorophenyl)-7-( t-butyl)pyrazolo[3,4- d] pyrimidine (pp2, a specific Src inhibitor) stimulated KCC independently.	AG 1879	17-83	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	85-88
12492401-9	2003	Furthermore, the observed DHA-induced doubling of the ratio of hypophosphorylated pRb (hypo-pRb) to total pRb is inhibited by tautomycin and phosphatidic acid (PA), known inhibitors of protein phosphatase 1 (PP1), and by the PP2 inhibitor okadaic acid.	Docosahexaenoic Acids	26-29	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	225-228
12492401-9	2003	Furthermore, the observed DHA-induced doubling of the ratio of hypophosphorylated pRb (hypo-pRb) to total pRb is inhibited by tautomycin and phosphatidic acid (PA), known inhibitors of protein phosphatase 1 (PP1), and by the PP2 inhibitor okadaic acid.	tautomycin	126-136	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	225-228
12492401-9	2003	Furthermore, the observed DHA-induced doubling of the ratio of hypophosphorylated pRb (hypo-pRb) to total pRb is inhibited by tautomycin and phosphatidic acid (PA), known inhibitors of protein phosphatase 1 (PP1), and by the PP2 inhibitor okadaic acid.	Phosphatidic Acids	141-158	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	225-228
12679489-0	2003	Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).	AG 1879	77-141	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	143-146
12679489-3	2003	Here, we show that 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) (PP2), another pyrazolopyrimidine, blocks the enzymatic activity of the isolated RET kinase and RET/PTC1 oncoprotein at IC(50) in the nanomolar range.	AG 1879	19-84	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	86-89
12679489-3	2003	Here, we show that 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) (PP2), another pyrazolopyrimidine, blocks the enzymatic activity of the isolated RET kinase and RET/PTC1 oncoprotein at IC(50) in the nanomolar range.	1H-pyrazolo[4,3-d]pyrimidine	100-118	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	86-89
12707358-2	2003	A protein kinase C (PKC) inhibitor (staurosporine), tyrosine kinase inhibitors (genistein and herbimycin A), or a Src kinase inhibitor (PP2) attenuated TNF-alpha- or 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced COX-2 promoter activity.	Tetradecanoylphorbol Acetate	166-202	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	136-139
12707358-2	2003	A protein kinase C (PKC) inhibitor (staurosporine), tyrosine kinase inhibitors (genistein and herbimycin A), or a Src kinase inhibitor (PP2) attenuated TNF-alpha- or 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced COX-2 promoter activity.	Tetradecanoylphorbol Acetate	204-207	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	136-139
12531734-6	2003	However, in rabbits pretreated with DETA/NO + PP2 (n = 5), the total deficit of WTh was significantly greater than that in rabbits treated with DETA/NO alone and was similar to that in controls, indicating that PP2 prevented the development of DETA/NO-induced late PC.	diethylenetriamine	36-40	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	211-214
12645577-2	2003	TNF-alpha- or 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ICAM-1 promoter activity was inhibited by a protein kinase C (PKC) inhibitor (staurosporine), tyrosine kinase inhibitors (genistein and herbimycin A), or an Src-specific tyrosine kinase inhibitor (PP2).	Tetradecanoylphorbol Acetate	52-55	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	262-265
12431978-4	2003	The Src family kinase specific-inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) abrogates 17beta-estradiol- but not ionomycin-stimulated NO release.	AG 1879	41-104	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	106-109
12388102-5	2003	CCh-induced p38 phosphorylation was attenuated by the EGFR inhibitor tyrphostin AG-1478 (0.1 nM-10 microM) and by the Src family kinase inhibitor PP2 (20 nM-2 microM).	Carbachol	0-3	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	146-149
12606588-6	2003	Although the tyrosine kinase inhibitor PP2 abolished the thapsigargin-induced increase in protein phosphotyrosine content, it did not affect the intracellular Ca( 2+) concentration or the percentage of acrosome-reacted sperm.	Thapsigargin	57-69	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	39-42
12606588-6	2003	Although the tyrosine kinase inhibitor PP2 abolished the thapsigargin-induced increase in protein phosphotyrosine content, it did not affect the intracellular Ca( 2+) concentration or the percentage of acrosome-reacted sperm.	Phosphotyrosine	98-113	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	39-42
12606029-3	2003	Despite the detailed structural information on Hck-PP1 and Lck-PP2 complexes, which shows that PP1 and PP2 bind to the adenosine triphosphate (ATP) pocket, we were unable to improve the affinity between modified PP1 and Src.	Adenosine Triphosphate	119-141	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	103-106
12606029-3	2003	Despite the detailed structural information on Hck-PP1 and Lck-PP2 complexes, which shows that PP1 and PP2 bind to the adenosine triphosphate (ATP) pocket, we were unable to improve the affinity between modified PP1 and Src.	Adenosine Triphosphate	143-146	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	103-106
12475982-5	2003	SCF-induced c-Kit phosphorylation was also inhibited by the related inhibitor 4-amino-5- (4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidine (PP2) and by STI571 but not by the Src inhibitor SU6656.	AG 1879	78-143	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	145-148
12431978-4	2003	The Src family kinase specific-inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) abrogates 17beta-estradiol- but not ionomycin-stimulated NO release.	Estradiol	121-137	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	106-109
12431978-4	2003	The Src family kinase specific-inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) abrogates 17beta-estradiol- but not ionomycin-stimulated NO release.	Ionomycin	147-156	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	106-109
12431978-5	2003	Consistent with these results, PP2 blocked 17beta-estradiol-induced Akt phosphorylation but did not inhibit NO release from cells transduced with a constitutively active Akt.	Estradiol	43-59	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	31-34
12431978-6	2003	PP2 abrogated 17beta-estradiol-induced activation of PI3-kinase, indicating that the PP2-inhibitable kinase is upstream of PI3-kinase and Akt.	Estradiol	14-30	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
12431978-6	2003	PP2 abrogated 17beta-estradiol-induced activation of PI3-kinase, indicating that the PP2-inhibitable kinase is upstream of PI3-kinase and Akt.	Estradiol	14-30	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	85-88
12414812-3	2003	Aplidin-induced apoptosis was only partially blocked by the general caspase inhibitor benzyloxycarbonyl-VAD-fluoromethyl ketone and was also sensitive to AG1478 (an EGFR inhibitor), PP2 (an Src inhibitor), and SB203580 (an inhibitor of JNK and p38 MAPK) in MDA-MB-231 cells.	plitidepsin	0-7	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	182-185
12429743-6	2003	In contrast, inhibition of c-Src by pp2 treatment or in c-Src (-/-) knockout cell lines, demonstrated a significant reduction in I kappa B alpha tyrosine phosphorylation and NF kappa B activation following pervanadate or H/R treatment.	Tyrosine	145-153	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	36-39
12429743-6	2003	In contrast, inhibition of c-Src by pp2 treatment or in c-Src (-/-) knockout cell lines, demonstrated a significant reduction in I kappa B alpha tyrosine phosphorylation and NF kappa B activation following pervanadate or H/R treatment.	pervanadate	206-217	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	36-39
12372346-7	2002	In addition, the EGF-induced phosphorylation of caveolin-1 in A431 cells was blocked by the Src kinase antagonists PP1 and PP2, but not by the MEK inhibitor PD98059, the phosphoinositide 3-kinase inhibitors LY294002 and wortmannin, or cytoskeleton-disrupting agents, such as cytochalasin D, colchicine, and nocadazole.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	207-215	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	123-126
12573708-11	2003	In addition, the rise in transepithelial electrical resistance induced by eicosapentaenoic acids and gamma linolenic acid was markedly inhibited by the tyrosine kinase inhibitors genistein and PP2 and protein kinase C inhibitor, calphostin C.	Eicosapentaenoic Acid	74-96	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	193-196
12573708-11	2003	In addition, the rise in transepithelial electrical resistance induced by eicosapentaenoic acids and gamma linolenic acid was markedly inhibited by the tyrosine kinase inhibitors genistein and PP2 and protein kinase C inhibitor, calphostin C.	gamma-Linolenic Acid	101-121	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	193-196
12573708-11	2003	In addition, the rise in transepithelial electrical resistance induced by eicosapentaenoic acids and gamma linolenic acid was markedly inhibited by the tyrosine kinase inhibitors genistein and PP2 and protein kinase C inhibitor, calphostin C.	calphostin C	229-241	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	193-196
12435806-5	2002	HU-210-induced ERK activation was inhibited by tyrphostin AG1478 and PP2, widely employed inhibitors of the epidermal growth factor receptor (EGF(R)) and the Src family of cytosolic tyrosine kinases, respectively.	HU 211	0-6	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	69-72
12202486-7	2002	Co-incubation with the Src kinase inhibitor PP2 and anti-EGFr had an additive inhibitory effect on CCh-induced ERK phosphorylation greater than either inhibitor alone.	Carbachol	99-102	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	44-47
12391293-4	2002	Functional experiments in human and rat show that inhibitors of Src (Lavendustin A, PP2) but not inactive compounds (Lavendustin B, PP3) induce a pronounced relaxation of coronary or aortic smooth muscle precontracted with 5-hydroxytriptamine, phenylephrine, or Angiotensin II.	Serotonin	223-242	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	84-87
12391293-4	2002	Functional experiments in human and rat show that inhibitors of Src (Lavendustin A, PP2) but not inactive compounds (Lavendustin B, PP3) induce a pronounced relaxation of coronary or aortic smooth muscle precontracted with 5-hydroxytriptamine, phenylephrine, or Angiotensin II.	Phenylephrine	244-257	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	84-87
12391293-5	2002	Iberiotoxin, a MaxiK blocker, antagonizes the relaxation induced by Lavendustin A or PP2, indicating that c-Src inhibits the Iberiotoxin-sensitive component, likely MaxiK channels.	iberiotoxin	0-11	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	85-88
12391293-5	2002	Iberiotoxin, a MaxiK blocker, antagonizes the relaxation induced by Lavendustin A or PP2, indicating that c-Src inhibits the Iberiotoxin-sensitive component, likely MaxiK channels.	iberiotoxin	125-136	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	85-88
12372346-7	2002	In addition, the EGF-induced phosphorylation of caveolin-1 in A431 cells was blocked by the Src kinase antagonists PP1 and PP2, but not by the MEK inhibitor PD98059, the phosphoinositide 3-kinase inhibitors LY294002 and wortmannin, or cytoskeleton-disrupting agents, such as cytochalasin D, colchicine, and nocadazole.	Wortmannin	220-230	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	123-126
12372346-7	2002	In addition, the EGF-induced phosphorylation of caveolin-1 in A431 cells was blocked by the Src kinase antagonists PP1 and PP2, but not by the MEK inhibitor PD98059, the phosphoinositide 3-kinase inhibitors LY294002 and wortmannin, or cytoskeleton-disrupting agents, such as cytochalasin D, colchicine, and nocadazole.	Cytochalasin D	275-289	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	123-126
12372346-7	2002	In addition, the EGF-induced phosphorylation of caveolin-1 in A431 cells was blocked by the Src kinase antagonists PP1 and PP2, but not by the MEK inhibitor PD98059, the phosphoinositide 3-kinase inhibitors LY294002 and wortmannin, or cytoskeleton-disrupting agents, such as cytochalasin D, colchicine, and nocadazole.	Colchicine	291-301	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	123-126
12372346-7	2002	In addition, the EGF-induced phosphorylation of caveolin-1 in A431 cells was blocked by the Src kinase antagonists PP1 and PP2, but not by the MEK inhibitor PD98059, the phosphoinositide 3-kinase inhibitors LY294002 and wortmannin, or cytoskeleton-disrupting agents, such as cytochalasin D, colchicine, and nocadazole.	nocadazole	307-317	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	123-126
12070037-4	2002	These events seem to be mediated by Src-like catalyzed phosphorylation of band 3 because both SHP-2 translocation to cellular membranes and its interaction with Tyr-phosphorylated protein are greatly counteracted by PP2, a specific inhibitor of Src kinases.	Tyrosine	161-164	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	216-219
12358796-10	2002	The src family tyrosine kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d]pyrimidine (PP2), but not its inactive analog PP3, abolished the effects of SIN-1.	AG 1879	41-105	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	107-110
12060669-7	2002	PP2 did not inhibit the association of cortactin with E-selectin and ICAM-1; however, PP2 inhibited adhesion between paraformaldehyde-fixed THP-1 cells and ECs.	paraform	117-133	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	86-89
11677248-10	2002	PP2, a Src family kinase inhibitor, or cytochalasin D, which selectively disrupts the network of actin filaments, inhibited both FAK phosphorylation and NO production induced by FN-f, but the phosphatidylinositol 3-kinase inhibitor wortmannin had no effect.	fn-f	178-182	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
12003786-6	2002	Moreover, PDGF-induced thymidine uptake was completely blocked by pretreatment of HASMC with the STAT kinase inhibitors AG-490, SU-6656, and PP2.	Thymidine	23-32	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	141-144
12003786-6	2002	Moreover, PDGF-induced thymidine uptake was completely blocked by pretreatment of HASMC with the STAT kinase inhibitors AG-490, SU-6656, and PP2.	hasmc	82-87	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	141-144
11879813-6	2002	Further, the CEE-potentiated glutamate response was mediated by a src tyrosine kinase, as the tyrosine kinase inhibitor PP2 blocked the potentiation induced by CEE and neurons treated with CEE displayed increased phosphorylated tyrosine.	Glutamic Acid	29-38	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	120-123
11879813-6	2002	Further, the CEE-potentiated glutamate response was mediated by a src tyrosine kinase, as the tyrosine kinase inhibitor PP2 blocked the potentiation induced by CEE and neurons treated with CEE displayed increased phosphorylated tyrosine.	Tyrosine	70-78	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	120-123
11996950-9	2002	Use of specific tyrosine kinase inhibitor herbimycin A, genistein, or PP2 (Src family kinase inhibitor) indicated that tyrosine kinases are required for IL-1beta-stimulated and beta-VLDL-enhanced nitrite accumulation, while specific inhibition of ERK1/2 or p38-MAP kinase had no effects.	Nitrites	196-203	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	70-73
11677248-10	2002	PP2, a Src family kinase inhibitor, or cytochalasin D, which selectively disrupts the network of actin filaments, inhibited both FAK phosphorylation and NO production induced by FN-f, but the phosphatidylinositol 3-kinase inhibitor wortmannin had no effect.	Wortmannin	232-242	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
11696015-4	2001	Inhibition of Src with the specific inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) completely blocked VEGF-induced Y861 phosphorylation without decreasing the level of phospho-Y397 FAK.	AG 1879	46-109	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	111-114
11694531-6	2002	UV-induced ERK activation was accompanied with the Tyr phosphorylation of EGF receptors, and both responses were completely abolished in the presence of a selective EGF receptor inhibitor (AG1478) or the Src inhibitor PP2 and by the expression of a kinase-dead Src mutant.	Tyrosine	51-54	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	218-221
11914123-7	2002	The Src kinase inhibitors PP1 and PP2 partially diminished the ERK responses elicited by both norepinephrine and PGF2alpha.	Norepinephrine	94-108	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	34-37
11914123-7	2002	The Src kinase inhibitors PP1 and PP2 partially diminished the ERK responses elicited by both norepinephrine and PGF2alpha.	Dinoprost	113-122	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	34-37
11756483-5	2002	The tyrosine phosphorylation was blocked by addition of the Src family tyrosine kinase inhibitor 4-amino-5-(4-chlorophenyl)-7(t-butyl)pyrazol(3,4-d)pyramide (PP2) and the phosphatidylinositol 3-kinase inhibitor LY 294002.	Tyrosine	4-12	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	158-161
11756483-5	2002	The tyrosine phosphorylation was blocked by addition of the Src family tyrosine kinase inhibitor 4-amino-5-(4-chlorophenyl)-7(t-butyl)pyrazol(3,4-d)pyramide (PP2) and the phosphatidylinositol 3-kinase inhibitor LY 294002.	pyrazole	133-141	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	158-161
11756483-5	2002	The tyrosine phosphorylation was blocked by addition of the Src family tyrosine kinase inhibitor 4-amino-5-(4-chlorophenyl)-7(t-butyl)pyrazol(3,4-d)pyramide (PP2) and the phosphatidylinositol 3-kinase inhibitor LY 294002.	pyramide	148-156	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	158-161
11756483-5	2002	The tyrosine phosphorylation was blocked by addition of the Src family tyrosine kinase inhibitor 4-amino-5-(4-chlorophenyl)-7(t-butyl)pyrazol(3,4-d)pyramide (PP2) and the phosphatidylinositol 3-kinase inhibitor LY 294002.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	211-220	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	158-161
11546805-3	2001	Src kinase inhibitor PP2 blocked ET-1-induced Src kinase activity, Galpha(q/11) tyrosine phosphorylation, and glucose transport stimulation.	Glucose	110-117	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	21-24
11546805-3	2001	Src kinase inhibitor PP2 blocked ET-1-induced Src kinase activity, Galpha(q/11) tyrosine phosphorylation, and glucose transport stimulation.	Tyrosine	80-88	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	21-24
11369760-6	2001	CD44-mediated cell spreading and induced tyrosine phosphorylation were prevented by the Src family kinase inhibitor, PP2.	Tyrosine	41-49	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	117-120
11535829-6	2001	In PP2-treated cells, Pyk2, paxillin, and some other proteins showed a decrease in tyrosine phosphorylation, and the enhancement of tyrosine phosphorylation of these proteins in response to Ca(2+) influx was also reduced.	Tyrosine	83-91	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	3-6
11535829-6	2001	In PP2-treated cells, Pyk2, paxillin, and some other proteins showed a decrease in tyrosine phosphorylation, and the enhancement of tyrosine phosphorylation of these proteins in response to Ca(2+) influx was also reduced.	Tyrosine	132-140	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	3-6
11535829-7	2001	Electron and fluorescence microscopy showed that PP2 treatment induced morphological change and decreased phalloidin reactivity at the filopodium-like structures on the processes of PC12 cells.	Phalloidine	106-116	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	49-52
11641791-8	2001	The tyrosine phosphorylation level of STAT5 induced by EPO in F-36P cells was reduced in the presence of PP1 or PP2 selective Src inhibitor.	Tyrosine	4-12	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	112-115
11445557-4	2001	Epidermal growth factor treatment induces tyrosine phosphorylation of Akt in COS1 and PC3M cells, which is abrogated by PP2, a selective inhibitor for Src family tyrosine kinases.	Tyrosine	42-50	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	120-123
11454659-7	2001	UK14304-induced contractions were inhibited by PP2 (1 - 10 microM), a selective inhibitor of Src tyrosine kinases, but not by PP3, an inactive analogue.	Brimonidine Tartrate	0-7	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	47-50
11454659-8	2001	PP2 also prevented the phosphorylation of Erk by UK14304.	Brimonidine Tartrate	49-56	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
11389697-8	2001	Cortactin tyrosine phosphorylation was blocked by Syk kinase inhibitor, piceatannol or Src family kinase inhibitor, PP2, suggesting that it depends on these two kinases.	Tyrosine	10-18	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	116-119
11278982-4	2001	In contrast, the tyrosine kinase inhibitors, genistein, herbimycin A, and 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) significantly attenuated H(2)O(2)-induced JNK activation as did endothelial cell adenoviral transfection with a dominant-negative form of Src, implicating Src as an upstream activator of JNK.	AG 1879	74-137	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	139-142
11274196-9	2001	The pretreatment of monocytes with the Src inhibitor AG1879: 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolol[3,4-d]pyrimidine (PP2) prior to stimulation with sE-selectin markedly inhibited Hck and Lyn phosphorylation, whereas the phosphorylation of Src was partially inhibited.	AG 1879	53-59	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	127-130
11274196-9	2001	The pretreatment of monocytes with the Src inhibitor AG1879: 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolol[3,4-d]pyrimidine (PP2) prior to stimulation with sE-selectin markedly inhibited Hck and Lyn phosphorylation, whereas the phosphorylation of Src was partially inhibited.	4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolol[3,4-d]pyrimidine	61-125	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	127-130
11357057-7	2001	Treatments for 6 or 48 h with PP2 (0.3 microM-10 microM) inhibited basal, Ang IotaIota, K(+) and dibutyryladenosine cyclic monophosphate (dbcAMP) stimulation of aldosterone production in a concentration-dependent manner.	Bucladesine	138-144	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	30-33
11357057-7	2001	Treatments for 6 or 48 h with PP2 (0.3 microM-10 microM) inhibited basal, Ang IotaIota, K(+) and dibutyryladenosine cyclic monophosphate (dbcAMP) stimulation of aldosterone production in a concentration-dependent manner.	Aldosterone	161-172	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	30-33
11357057-9	2001	Moreover, time course studies using PP2 (10 microM) for 6, 12, 24, and 48 h revealed a time-dependent inhibition of aldosterone production.	Aldosterone	116-127	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	36-39
11357057-10	2001	Inhibition by PP2 (0.3-10 microM) was also observed for the metabolism of 22R-hydroxycholesterol (22R-OHChol) to aldosterone in H295R cells.	22-hydroxycholesterol	74-96	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	14-17
11357057-10	2001	Inhibition by PP2 (0.3-10 microM) was also observed for the metabolism of 22R-hydroxycholesterol (22R-OHChol) to aldosterone in H295R cells.	22r-ohchol	98-108	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	14-17
11357057-10	2001	Inhibition by PP2 (0.3-10 microM) was also observed for the metabolism of 22R-hydroxycholesterol (22R-OHChol) to aldosterone in H295R cells.	Aldosterone	113-124	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	14-17
11357057-11	2001	Since 22R-OHChol is a substrate for cytochrome P450 side-chain cleavage enzyme (CYP11A) that does not require steroidogenic acute regulatory (StAR) protein for transport to the inner mitochondrial membrane, these results suggest that PP2 inhibition occurred beyond the rate-limiting step in aldosterone synthesis.	22r-ohchol	6-16	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	234-237
11357057-11	2001	Since 22R-OHChol is a substrate for cytochrome P450 side-chain cleavage enzyme (CYP11A) that does not require steroidogenic acute regulatory (StAR) protein for transport to the inner mitochondrial membrane, these results suggest that PP2 inhibition occurred beyond the rate-limiting step in aldosterone synthesis.	Aldosterone	291-302	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	234-237
11357057-14	2001	To further investigate the site of PP2 action, we examined its effect on H295R cell metabolism of [(14)C]progesterone using thin layer chromatography.	[(14)c]progesterone	98-117	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	35-38
11357057-15	2001	PP2 treatment for 48 h caused an increase in the conversion of progesterone to 17alpha-hydroxyprogesterone.	Progesterone	63-75	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
11357057-15	2001	PP2 treatment for 48 h caused an increase in the conversion of progesterone to 17alpha-hydroxyprogesterone.	17-alpha-Hydroxyprogesterone	79-106	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
11357057-18	2001	Inhibition of protein synthesis with cycloheximide increased basal levels of CYP17 mRNA levels and blocked the induction observed by PP2.	Cycloheximide	37-50	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	133-136
11357057-20	2001	Taken together these data suggest that the src tyrosine kinase inhibitor, PP2, is a potent inhibitor of aldosterone production.	Aldosterone	104-115	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	74-77
11278982-6	2001	Consistent with this observation, H(2)O(2) stimulated EGFR tyrosine phosphorylation and complex formation with Shc-Grb2 that was abolished by PP2, implicating Src in H(2)O(2)-induced EGFR activation.	Hydrogen Peroxide	34-42	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	142-145
11278982-6	2001	Consistent with this observation, H(2)O(2) stimulated EGFR tyrosine phosphorylation and complex formation with Shc-Grb2 that was abolished by PP2, implicating Src in H(2)O(2)-induced EGFR activation.	Hydrogen Peroxide	166-174	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	142-145
11357057-6	2001	In the present study we evaluated the effect of a selective src family inhibitor, PP2, on aldosterone production using a human adrenocortical carcinoma-derived (H295R) cell line.	Aldosterone	90-101	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	82-85
11357057-7	2001	Treatments for 6 or 48 h with PP2 (0.3 microM-10 microM) inhibited basal, Ang IotaIota, K(+) and dibutyryladenosine cyclic monophosphate (dbcAMP) stimulation of aldosterone production in a concentration-dependent manner.	Bucladesine	97-136	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	30-33
11278940-3	2001	Both the expression of dominant-negative Src and treatment with the 4-amine-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) inhibitor of Src kinase activity blocks agonist-induced desensitization.	4-amine-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine	68-131	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	133-136
11267999-4	2001	Accordingly, ERK1/2 phosphorylation induced by UTP was inhibited by the PI3K inhibitors, wortmannin and LY294002, and the c-src inhibitors, radicicol and PP2, but not by inhibitors of protein kinase C (PKC).	Uridine Triphosphate	47-50	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	154-157
11402496-4	2001	Genistein and PP2 additionally prevent Fc gamma R-triggered hydrogen peroxide generation.	Hydrogen Peroxide	60-77	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	14-17
11278940-8	2001	Constitutively active Src increases GRK phosphorylation, whereas either expression of dominant-negative Src or treatment with the PP2 inhibitor abolishes tyrosine phosphorylation of GRK and desensitization.	Tyrosine	154-162	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	130-133
10952984-4	2000	In contrast, the injury of endothelial cells mediated by H(2)O(2) is inhibited by PP2, a selective specific inhibitor for protein-tyrosine kinase Src.	Hydrogen Peroxide	57-65	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	82-85
11078745-6	2001	Tyrosine phosphorylation occurs primarily on tyrosine 125 and was inhibited by PP2, a selective inhibitor of Src protein-tyrosine kinase (PTK) family members at concentrations consistent with inhibition of Src function ().	Tyrosine	0-8	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	79-82
11230339-6	2001	Ang II-directed migration was also blocked by the Src kinase inhibitor PP2 (10 micromol/L), by the extracellular-regulated protein kinase (ERK 1/2) inhibitor PD98059 (30 micromol/L), and by the p38-MAPK inhibitor SB203580 (10 micromol/L), indicating that Src, ERK 1/2, and p38 are all involved in Ang II-induced migration of HPBM and human THP-1 monocytes.	SB 203580	213-221	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	71-74
10842168-5	2000	Furthermore, pretreatment with the selective Src family kinase inhibitor PP2 completely inhibited the ability of sorbitol treatment to cause tyrosine phosphorylation of Gab-1.	Sorbitol	113-121	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	73-76
10945993-5	2000	The tyrosine phosphorylation of PKCdelta and the decrease in GS expression induced by platelet-derived growth factor (PDGF) were abolished by the Src kinase inhibitors PP1 and PP2.	Tyrosine	4-12	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	176-179
10956618-5	2000	Tyrosine kinase inhibitors, genistein, and PP-2, a specific inhibitor of Src, reduced the DPV-mediated barrier dysfunction.	diperoxovanadate	90-93	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	43-47
10956618-6	2000	Consistent with these results, DPV-induced Src activation was attenuated by PP-2.	diperoxovanadate	31-34	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	76-80
10934208-6	2000	We found that the PP2C-like activity in HeLa cell extract, partially purified HeLa PP2C alpha and PP2C beta 2 isoforms, and the recombinant PP2Cs exhibited a comparable substrate preference for a phosphothreonine containing substrate, consistent with the conservation of threonine residues at the site of activating phosphorylation in CDKs.	Phosphothreonine	196-212	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	18-21
10934208-6	2000	We found that the PP2C-like activity in HeLa cell extract, partially purified HeLa PP2C alpha and PP2C beta 2 isoforms, and the recombinant PP2Cs exhibited a comparable substrate preference for a phosphothreonine containing substrate, consistent with the conservation of threonine residues at the site of activating phosphorylation in CDKs.	Threonine	203-212	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	18-21
11054117-9	2000	An inhibitor of Src kinase (PP2) decreased the peroxovanadate-induced PDK1 tyrosine phosphorylation and overexpression of v-Src stimulated this phosphorylation.	peroxovanadate	47-61	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	28-31
11054117-9	2000	An inhibitor of Src kinase (PP2) decreased the peroxovanadate-induced PDK1 tyrosine phosphorylation and overexpression of v-Src stimulated this phosphorylation.	Tyrosine	75-83	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	28-31
10842168-5	2000	Furthermore, pretreatment with the selective Src family kinase inhibitor PP2 completely inhibited the ability of sorbitol treatment to cause tyrosine phosphorylation of Gab-1.	Tyrosine	141-149	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	73-76
11164895-10	2000	Treatment of Jurkat cells with PP2, an inhibitor of p56(Lck), inhibited calcium-induced, but not PMA-induced, ERK1 and 2 activation.	Calcium	72-79	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	31-34
10880360-6	2000	We demonstrated that Tyr(139) of DAPP1 is likely to be phosphorylated in vivo by a Src-family tyrosine kinase, since the specific Src-family inhibitor, PP2, but not an inactive variant of this drug, PP3, prevented the agonist-induced tyrosine phosphorylation of DAPP1.	Tyrosine	21-24	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	152-155
10880360-6	2000	We demonstrated that Tyr(139) of DAPP1 is likely to be phosphorylated in vivo by a Src-family tyrosine kinase, since the specific Src-family inhibitor, PP2, but not an inactive variant of this drug, PP3, prevented the agonist-induced tyrosine phosphorylation of DAPP1.	Tyrosine	94-102	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	152-155
10788500-9	2000	In Vector cells, the 14,15-EET-stimulated tyrosine phosphorylation of ERKs was blocked by pretreatment with 1 microm PP2, a selective inhibitor of Src kinases.	Tyrosine	42-50	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	117-120
10809781-5	2000	Pervanadate induced shedding and rounding-up of cells from the substrate, which was blocked by the Src kinase inhibitor PP2.	pervanadate	0-11	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	120-123
10777553-9	2000	The Src family kinase inhibitor, PP2 (20 nM-20 microM) attenuated CCh-stimulated EGFR and ERK phosphorylation and potentiated chloride secretory responses to CCh.	Carbachol	66-69	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	33-36
10777553-9	2000	The Src family kinase inhibitor, PP2 (20 nM-20 microM) attenuated CCh-stimulated EGFR and ERK phosphorylation and potentiated chloride secretory responses to CCh.	Chlorides	126-134	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	33-36
10777553-9	2000	The Src family kinase inhibitor, PP2 (20 nM-20 microM) attenuated CCh-stimulated EGFR and ERK phosphorylation and potentiated chloride secretory responses to CCh.	Carbachol	158-161	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	33-36
10777558-6	2000	Last, the IFNalpha-induced serine phosphorylation of STAT1 and STAT3 is not inhibited by piceatannol but is sensitive to the Src kinase-specific inhibitor PP2.	Serine	27-33	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	155-158
10094466-3	1999	Gastrin-induced PI 3-kinase activity was coprecipitated with p60Src and p125FAK and was inhibited by herbimycin A, the selective Src inhibitor PP-2 or cytochalasin D, which disrupts the actin cytoskeleton and prevents p125FAK activity.	herbimycin	101-113	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	143-147
10404594-5	1999	RESULTS: We report here the high-resolution crystal structures of an activated Lck kinase domain in complex with three structurally distinct ATP-competitive inhibitors: AMP-PNP (a non-selective, non-hydrolyzable ATP analog); staurosporine (a potent but non-selective protein kinase inhibitor); and PP2 (a potent Src family selective protein tyrosine kinase inhibitor).	Adenosine Triphosphate	141-144	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	298-301
10404594-5	1999	RESULTS: We report here the high-resolution crystal structures of an activated Lck kinase domain in complex with three structurally distinct ATP-competitive inhibitors: AMP-PNP (a non-selective, non-hydrolyzable ATP analog); staurosporine (a potent but non-selective protein kinase inhibitor); and PP2 (a potent Src family selective protein tyrosine kinase inhibitor).	Adenylyl Imidodiphosphate	169-176	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	298-301
10404594-7	1999	Furthermore, PP2 is found to access a deep, hydrophobic pocket near the ATP-binding cleft of the enzyme; this binding pocket is not occupied by either AMP-PNP or staurosporine.	Adenosine Triphosphate	72-75	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	13-16
10404594-9	1999	In contrast, PP2 binds tightly and selectively to Lck and other Src family kinases by making additional contacts in a deep, hydrophobic pocket adjacent to the ATP-binding site; the amino acid composition of this pocket is unique to Src family kinases.	Adenosine Triphosphate	159-162	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	13-16
10374264-5	1999	Taking advantage of the reactivity of mAb PP2-150 with formalin-fixed, paraffin-embedded material, a series of human carcinomas (n = 37) has also been analyzed.	Formaldehyde	55-63	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	42-45
10206955-4	1999	Tyrosine phosphorylation of CD33 in myeloid cell lines was stimulated by cell surface cross-linking or by pervanadate, and inhibited by PP2, a specific inhibitor of Src family tyrosine kinases.	Tyrosine	0-8	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	136-139
1467652-4	1992	Sequence analysis of PP2 cDNAs revealed a 654-bp open reading frame encoding a 218-amino acid polypeptide; this polypeptide had the carbohydrate binding characteristics of a PP2 subunit.	Carbohydrates	132-144	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	21-24
7699860-2	1995	The PPs which had three components (PP1, PP2, PP3) were recorded in 14 of the 26 volunteers (53.8%) and 10 of the 15 VT patients (66.7%).	pps	4-7	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	41-44
9083477-4	1997	Thirdly, compounds with hydrogen bond-accepting or-donating groups attached to the phenyl groups in the P2 and P2" side chains (6 and 7) were selected.	Hydrogen	24-32	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	104-113
1467652-4	1992	Sequence analysis of PP2 cDNAs revealed a 654-bp open reading frame encoding a 218-amino acid polypeptide; this polypeptide had the carbohydrate binding characteristics of a PP2 subunit.	Carbohydrates	132-144	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	174-177
1467652-5	1992	The PP2 mRNA was localized within the phloem of pumpkin hypocotyl cross-sections based on in situ hybridization of a digoxigenin-labeled antisense probe.	Digoxigenin	117-128	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	4-7
35072063-12	2021	During PP2, when the COVID-19 lockdown was in place, the proportion of time spent in Z3 doubled, while that spent in Z1 was lowered; the total time spent training on water increased; these changes may have accentuated the improvement in performance during this period.	Water	166-171	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	7-10
34975519-9	2021	PP2, a Src inhibitor, partially imitated the effect of QSYQ.	qsyq	55-59	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
2152934-6	1990	delta 5-17P/17-OHP for PP1 vs. PP2, PP2 vs. PP3, and PP1 vs. PP3 were significantly different (P less than 0.05) by analysis of variance and multiple comparison testing using the Student-Newman-Keuls procedure.	17-alpha-Hydroxyprogesterone	12-18	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	31-34
35586977-4	2022	APPROACH AND RESULTS: Using A549 cells transduced with a lentivirus K18 construct and high-throughput screening, we identified the SRC-family tyrosine kinases inhibitor, PP2, as a compound that reverses keratin filament disruption and protects from apoptotic cell death caused by K18 R90C mutation at this highly conserved arginine.	Arginine	323-331	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	170-173
33503805-6	2021	In the presence of the selective inhibitor for SRC-family kinases PP2, the effects of DPN and PPT on transmigration and soft agar colony formation assays were decreased.	NAD	86-89	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	66-69
5497803-0	1970	pP2 of eserine and neostigmine on acetylcholine responses of isolated ileum.	Acetylcholine	34-47	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
33503805-6	2021	In the presence of the selective inhibitor for SRC-family kinases PP2, the effects of DPN and PPT on transmigration and soft agar colony formation assays were decreased.	Agar	125-129	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	66-69
32473212-3	2020	Using this strategy, we have synthesized a small series of Boc-FDeltaF-AH-polyethylenimine conjugates by varying the concentration of Boc-FDeltaF-aminohexanoic acid, viz., PP-1, PP-2 and PP-3.	boc-fdeltaf-ah-polyethylenimine	59-90	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	178-182
32721671-6	2020	Inhibitors of c-SRC (PP2) and MEK (PD98059) suppressed the lithium-induced increase in anchorage-independent growth of the keratinocytes.	Lithium	59-66	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	21-24
30880179-6	2019	L-NAME, ODQ, methylene blue and calmidazolium increased BPV-induced contraction in endothelium-intact aortae, whereas PP2 alone and combined treatment with L-arginine and L-NAME inhibited BPV-induced contraction.	Arginine	156-166	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	118-121
31729029-5	2020	Src action on TRPM8 potentiates its activity, as treatment with PP2, a selective Src kinase inhibitor, reduces both TRPM8 tyrosine phosphorylation and cold-induced channel activation.	Tyrosine	122-130	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	64-67
31729029-7	2020	Finally, the effect of PP2 on TRPM8 cold activation was reproduced in cultured rat dorsal root ganglion neurons, and this action was antagonized by the protein tyrosine phosphatase inhibitor pervanadate, confirming that TRPM8 activity is sensitive to the cellular balance between tyrosine kinases and phosphatases.	Tyrosine	160-168	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	23-26
31729029-7	2020	Finally, the effect of PP2 on TRPM8 cold activation was reproduced in cultured rat dorsal root ganglion neurons, and this action was antagonized by the protein tyrosine phosphatase inhibitor pervanadate, confirming that TRPM8 activity is sensitive to the cellular balance between tyrosine kinases and phosphatases.	pervanadate	191-202	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	23-26
31729029-7	2020	Finally, the effect of PP2 on TRPM8 cold activation was reproduced in cultured rat dorsal root ganglion neurons, and this action was antagonized by the protein tyrosine phosphatase inhibitor pervanadate, confirming that TRPM8 activity is sensitive to the cellular balance between tyrosine kinases and phosphatases.	Tyrosine	280-288	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	23-26
31891230-8	2020	When PP2 was administered with gefitinib, the same effects were seen.	gefitinib	31-40	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	5-8
31407399-4	2020	Here we report that the action potential (AP) firing activity of ARC neurons in culture was up-regulated by application of the adenylate cyclase activator forskolin or the PKC activator PMA, and that the forskolin or PMA application-induced up-regulation of AP firing activity could be blocked by pre-application of the SFK inhibitor PP2.	Colforsin	155-164	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	334-337
31194565-6	2019	Interestingly, PP2-mediated suppression of hASBT protein expression was rescued by the proteasome inhibitor MG132, suggesting that dephosphorylation impacts protein stability with the subsequent proteasome-dependent degradation of hASBT.	benzyloxycarbonylleucyl-leucyl-leucine aldehyde	108-113	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	15-18
31308219-8	2019	BPM3 and BPM5 accelerate the turnover of PP2Cs in an ABA-dependent manner and their overexpression leads to enhanced ABA sensitivity, whereas bpm3 bpm5 plants show increased accumulation of PP2CA, ABI1 and HAB1, which leads to global diminished ABA sensitivity.	Abscisic Acid	53-56	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	41-44
31988091-3	2020	Polyphyllin II (PP2), an important steroidal saponin extracted from Rhizoma Paris, has emerged as a potential anticancer agent, but the effects of PP2 in liver cancers and its underlying mechanisms remain unexplored.	polyphyllin H	0-14	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	16-19
31988091-3	2020	Polyphyllin II (PP2), an important steroidal saponin extracted from Rhizoma Paris, has emerged as a potential anticancer agent, but the effects of PP2 in liver cancers and its underlying mechanisms remain unexplored.	Saponins	35-52	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	16-19
31815763-4	2020	The SRC kinase inhibitor PP2 increased the expression of total Cx43 protein and enhanced cisplatin sensitivity, indicating that activated SRC kinase induces chemoresistance by decrease total Cx43 level.	Cisplatin	89-98	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	25-28
31815763-6	2020	Taken together, targeting SRC kinase by PP2 reverses cisplatin resistance by upregulating Cx43 protein levels, indicating a novel pathway of cisplatin resistance that may be amenable to therapeutic intervention.	Cisplatin	53-62	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	40-43
31815763-6	2020	Taken together, targeting SRC kinase by PP2 reverses cisplatin resistance by upregulating Cx43 protein levels, indicating a novel pathway of cisplatin resistance that may be amenable to therapeutic intervention.	Cisplatin	141-150	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	40-43
31550527-8	2019	Moreover, RSV and a selective inhibitor of SFKs (PP2) reduced the phosphorylation of Bruton"s tyrosine kinase and Vav.	resveratrol	10-13	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	49-52
31550527-8	2019	Moreover, RSV and a selective inhibitor of SFKs (PP2) reduced the phosphorylation of Bruton"s tyrosine kinase and Vav.	Tyrosine	94-102	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	49-52
31340912-2	2019	METHODS: MTT assay was used to evaluate the inhibitory effect of PP2 on the proliferation of A549 cells.	monooxyethylene trimethylolpropane tristearate	9-12	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	65-68
31340912-4	2019	RESULTS: MTT assay showed that treatment with PP2 at 2, 4, 8, 16, and 32 mumol/L significantly inhibited the proliferation of A549 cells in a concentration-dependent manner.	monooxyethylene trimethylolpropane tristearate	9-12	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	46-49
31340912-7	2019	Overexpression of Cx43 significantly enhanced the inhibitory effect of PP2 on the cell invasion and metastasis, and Cx43 silencing significantly attenuated the inhibitory effect of PP2 (P < 0.05).	Adenosine Monophosphate	188-192	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	181-184
30880179-6	2019	L-NAME, ODQ, methylene blue and calmidazolium increased BPV-induced contraction in endothelium-intact aortae, whereas PP2 alone and combined treatment with L-arginine and L-NAME inhibited BPV-induced contraction.	NG-Nitroarginine Methyl Ester	171-177	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	118-121
30880179-9	2019	Additionally, phosphorylation of Src kinase, caveolin-1 and inhibitory eNOS (Thr495) induced by low-concentration BPV was inhibited by PP2.	Bupivacaine	114-117	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	135-138
30529557-1	2019	Pumpkin polysaccharide was extracted with hot water, and it was chemically modified with phosphorus oxychloride-pyridine to obtain phosphorylated pumpkin polysaccharides (PP1, PP2) with different degrees of substitution.	pumpkin polysaccharide	0-22	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	176-179
31944030-2	2019	Here, we demonstrate the 1,3-dipolar cycloaddition between PAMY and 1,4-diphenylbut-2-yne-1,4-dione and the subsequent condensation reaction with hydrazine, which led to unique N-PAHs with a phenyl-substituted pyrrolopyridazine core (PP-1 and PP-2).	1,4-diphenylbut-2-ene-1,4-dione	68-99	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	243-247
31944030-2	2019	Here, we demonstrate the 1,3-dipolar cycloaddition between PAMY and 1,4-diphenylbut-2-yne-1,4-dione and the subsequent condensation reaction with hydrazine, which led to unique N-PAHs with a phenyl-substituted pyrrolopyridazine core (PP-1 and PP-2).	hydrazine	146-155	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	243-247
31944030-2	2019	Here, we demonstrate the 1,3-dipolar cycloaddition between PAMY and 1,4-diphenylbut-2-yne-1,4-dione and the subsequent condensation reaction with hydrazine, which led to unique N-PAHs with a phenyl-substituted pyrrolopyridazine core (PP-1 and PP-2).	Pyrrolopyridazine	191-227	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	243-247
31212828-6	2019	The addition of 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d] pyrimidine (PP2), which is an inhibitor of Src kinase, significantly inhibited the mineralization process when evaluated by the above criteria.	AG 1879	16-81	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	83-86
30599064-11	2019	The c-Src and JNK inhibitors PP2 and SP600125 were able to increase the pHe, although the differences between control and CFTR-impaired cells were not fully compensated.	Phenylalanine	72-75	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	29-32
30625033-6	2019	Furthermore, the Src kinase inhibitor PP2 rescued cytokine-induced epithelial barrier defects and inhibited phosphorylation of JAM-A Y280 in vitro.	y280	133-137	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	38-41
30449206-9	2018	Any clinician considering switching patients to PP1M: 1) should switch from oral risperidone to PP1M rather than from oral paliperidone to PP1M, and 2) become proficient in paliperidone TDM to use during switches.	Paliperidone Palmitate	173-185	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	139-150
30414407-7	2018	When P1" is not proline, the orientations of the P2 and P2" side chains with respect to the scissile bond are reversed; P2 residues interact with a hydrophobic face of the S2 subsite, while the P2" amino acid usually engages hydrophilic amino acids in the S2" subsite.	Proline	16-23	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	49-58
30414407-8	2018	These results reveal that the HIV-1 PR has evolved bi-functional S2 and S2" subsites to accommodate the steric effects imposed by a P1" proline on the orientation of P2 and P2" substrate side chains.	Proline	136-143	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	166-175
30250573-6	2018	In the present study, the pyrazolopyrimidine compound PP2 was used to inhibit Src family protein tyrosine kinases in A549 cells.	1H-pyrazolo[4,3-d]pyrimidine	26-44	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	54-57
30470263-0	2018	Tonic ATP-mediated growth suppression in peripheral nerve glia requires arrestin-PP2 and is evaded in NF1.	Adenosine Triphosphate	6-9	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	81-84
29992946-3	2018	Here, we develop a "minimal component" protocol to generate late-stage pancreatic progenitors (PP2) that differentiate to mono-hormonal glucose-responding beta-like (PP2-beta) cells.	Glucose	136-143	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	95-98
30140808-5	2018	We converted a very weak EphA3-kinase ATP-binding site inhibitor-PP2 into a potent hetero-bivalent ligand by tethering to a unique 5-mer peptide sequence that derived from the linker region of EphA3 that connects kinase and sterile alpha motif (SAM) domains.	Adenosine Triphosphate	38-41	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	65-68
30378329-1	2018	OBJECTIVE: To investigate the role of SRC kinase inhibitor PP2 in drug resistance to adriamycin (ADM) in breast cancer cells and invasion, metastasis of cells.	Doxorubicin	85-95	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	59-62
30378329-1	2018	OBJECTIVE: To investigate the role of SRC kinase inhibitor PP2 in drug resistance to adriamycin (ADM) in breast cancer cells and invasion, metastasis of cells.	Doxorubicin	97-100	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	59-62
30158525-3	2018	Mechanistically, MHYs-induced Src/JNK activation which enhanced their pro-apoptotic effects and therefore inhibition of Src by the chemical inhibitor PP2 or Src siRNA abolished the response.	mhys	17-21	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	150-153
29978609-10	2018	Application of 10-DEBC with PP2 significantly reduced the metastatic potential of pancreatic cancer cells by inhibiting migration and invasion.	10-DEBC	15-22	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	28-31
29992946-3	2018	Here, we develop a "minimal component" protocol to generate late-stage pancreatic progenitors (PP2) that differentiate to mono-hormonal glucose-responding beta-like (PP2-beta) cells.	Glucose	136-143	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	166-169
29740790-8	2018	Further analysis revealed that the synergistic effects are dependent on SRC or MEK1/2 activities, as overexpression of SRC or MEK1/2 completely abrogated the synergistic effects SRC inhibitors (dasatinib and PP2) and MEK1/2 inhibitor (pimasertib).	N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide	235-245	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	208-211
29563255-6	2018	We also observed Cav-1 S-nitrosylation and destabilization of Cav-1 oligomers in cells treated with A23187 as well as insulin or albumin, and this could be blocked by L-NAME, PP2, or eNOS siRNA.	Calcimycin	100-106	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	175-178
29326556-7	2017	In parallel, we found that caveolin-1 (Cav1) is phosphorylated in response to H2O2 and that this is reversed by the Src kinase inhibitor 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).	Hydrogen Peroxide	78-82	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	202-205
29720121-12	2018	ER-c-Src-HER2 complex formation was also disrupted and tamoxifen resistance was reversed in BT474 cells by the c-Src inhibitor PP2 and HER2 antibody trastuzumab.	Tamoxifen	55-64	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	127-130
29466417-10	2018	Treatment with indomethacin, PP2, SB202190, and PD98059, respective inhibitors of COX enzymes, Src, p38MAPK, and ERK completely abrogated the effect of epinephrine.	Epinephrine	152-163	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	29-32
29466417-12	2018	Western blot analysis revealed an epinephrine-induced increase in the phosphorylation of p38 MAPK and ERK that disappeared in presence of respectively PP2 and SB2020190.	Epinephrine	34-45	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	151-154
29712570-7	2018	We further examined the role of sphingolipid signaling in the IL-1beta-mediated impairment of spine plasticity and found that both the neutral sphingomyelinase inhibitor GW4869 and the inhibitor of Src kinase PP2 attenuated the IL-1beta-mediated suppression of cLTP-induced surface expression of GluA1 and actin polymerization.	Sphingolipids	32-44	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	209-212
29712570-7	2018	We further examined the role of sphingolipid signaling in the IL-1beta-mediated impairment of spine plasticity and found that both the neutral sphingomyelinase inhibitor GW4869 and the inhibitor of Src kinase PP2 attenuated the IL-1beta-mediated suppression of cLTP-induced surface expression of GluA1 and actin polymerization.	cltp	261-265	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	209-212
29257221-5	2018	(E)-2-benzylidene-3-(cyclohexylamino)-2,3- dihydro-1H-inden-1-one (BCI) and calyculin A were employed as DUSP1/6 and PP1/PP2 inhibitors, respectively.	(e)-2-benzylidene-3-(cyclohexylamino)-2,3- dihydro-1h-inden-1-one	0-65	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	121-124
29257221-9	2018	The DUSP1/6 inhibitor, BCI, and the PP1/PP2 inhibitor, calyculin A, antagonized the beta2-adrenergic receptor-mediated dephosphorylation of ERK1/2.	calyculin A	55-66	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	40-43
29326556-7	2017	In parallel, we found that caveolin-1 (Cav1) is phosphorylated in response to H2O2 and that this is reversed by the Src kinase inhibitor 4-Amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).	AG 1879	137-200	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	202-205
29326556-8	2017	PP2 also abrogated the H2O2-induced increase in AQP4 surface levels, suggesting that  the phosphorylation of tyrosine-14 of Cav1 regulates  this  process.	Hydrogen Peroxide	23-27	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
29326556-8	2017	PP2 also abrogated the H2O2-induced increase in AQP4 surface levels, suggesting that  the phosphorylation of tyrosine-14 of Cav1 regulates  this  process.	Tyrosine	109-117	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
28343945-3	2017	We found that normalized phospho-SFK (PY416) signal is increased in postconfluent HPMECs compared to subconfluent cells and prior SFK inhibition with PP2 or SU6656 completely blocked NEU1 association with and desialylation of CD31.	py416	38-43	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	150-153
29192254-7	2017	PP2 decreased the cytosolic levels of pre-apoptotic proteins, attenuated the neuropathological changes and apoptosis and decreased the HI-induced increased activity of caspase-3.	hi	135-137	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
28765886-6	2017	An inhibitor of Src kinases, amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2), markedly reduced the effects of spermine.	amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine	29-90	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	92-95
28765886-6	2017	An inhibitor of Src kinases, amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2), markedly reduced the effects of spermine.	Spermine	130-138	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	92-95
28855900-8	2017	Further analyses with PP2 (10 microM, inhibitor of Src) indicated that DT-13 modulated endothelial permeability in TNF-alpha-induced HUVECs in an Src-dependent manner.	DT-13	71-76	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	22-25
27682013-12	2017	To test the involvement of SFKs in ROS production and cell death, we used SFK inhibitors PP2 and dasatinib, both of which completely inhibited eosinophil ROS production and cell death induced by anti-Siglec-8 and IL-5 co-stimulation.	Reactive Oxygen Species	154-157	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	89-92
28454121-8	2017	The invasiveness of the cells were suppressed by treating with sb203580 (p38/MAPK inhibitor) or HY-13805 (PP2, Src inhibitor).	pp2	96-104	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	106-109
28423613-7	2017	Moreover, inhibition of SRC by PP2 antagonized the resistance to sorafenib and inhibited the activation of STAT3 conferred by secreted GRP78.	Sorafenib	65-74	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	31-34
28072464-7	2017	On the other hand, the Src family kinase inhibitor PP2 (1 muM) slightly enhanced IKur and hKv 1.5 current, and the current increase was also reversed by orthovanadate.	Vanadates	153-166	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	51-54
28072464-8	2017	Immunoprecipitation and Western blotting analysis showed that genistein, AG556, and PP2 decreased tyrosine phosphorylation of hKv 1.5 channels and that the decrease was countered by orthovanadate.	Tyrosine	98-106	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	84-87
28072464-9	2017	CONCLUSION AND IMPLICATIONS: The PTK inhibitors genistein and AG556 decrease human atrial IKur and cloned hKv 1.5 channels by inhibiting EGFR TK, whereas the Src kinase inhibitor PP2 increases IKur and hKv 1.5 current.	Genistein	48-57	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	179-182
28072464-9	2017	CONCLUSION AND IMPLICATIONS: The PTK inhibitors genistein and AG556 decrease human atrial IKur and cloned hKv 1.5 channels by inhibiting EGFR TK, whereas the Src kinase inhibitor PP2 increases IKur and hKv 1.5 current.	AG 556	62-67	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	179-182
28088327-8	2017	ROS levels were partially reduced by incubation with PP2 (c-Src inhibitor) or IL1RN, and further reduced by using the NOX1/4 inhibitor GKT137831.	ros	0-3	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	53-56
27222231-7	2017	Both G-15 (an antagonist of GPR30, 0.1 mumol/L) and PP2 (an inhibitor of Src, 2.0 mumol/L) inhibited 17beta-estradiol-induced activation of PI3K, reduced SC proliferation, and decreased messenger RNA (mRNA) and protein expression of S-phase kinase-associated protein 2 (Skp2).	Estradiol	101-117	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	52-55
28011194-4	2017	Inhibition of Src activity by PP2 or Src dominant-negative mutants reduced 12-LOX tyrosine phosphorylation and 12(S)-HETE production in response to integrin beta4 stimulation in A431 cells.	12-Hydroxy-5,8,10,14-eicosatetraenoic Acid	111-121	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	30-33
27638545-8	2016	This may result from cytoskeletal deorganization, which was observed in response to AZM475271 and PP2 in WPMY-1 cells by staining of actin filaments with phalloidin.	Phalloidine	154-164	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	98-101
27459393-8	2016	The phosphorylation of Src and PKCdelta was suppressed by CLI-095, and the activation of ERK1/2, p38 MAPK, and JNK was inhibited by CLI-095, PP2, and rottlerin.	rottlerin	150-159	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	141-144
27742830-8	2016	Treatment of Jurkat cells with PP2, an inhibitor of Src family kinase, inhibited calcium-induced, but not PMA-induced, ERK phosphorylation.	Calcium	81-88	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	31-34
27545829-8	2016	Peptides modified with a 22 kDa PEG (PEG22) remained intact in blood plasma and on incubation with liver homogenates for more than 96 h. Finally, hPP2-36 , [K22 (PEG22)]hPP2-36 and [K22 (PEG22),Q34 ]hPP significantly reduced cumulative food intake in mice over 16 h after s.c. administration.	PEG22	37-42	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	169-173
27586187-2	2016	We have previously developed a novel formulation strategy to deliver a hydrophobic Src inhibitor, PP2, involving combinations of one self-assembling peptide (SAP) and one of 4 selected amino acids (AAs).	Amino Acids	198-201	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	98-101
27586187-9	2016	PP2 formulated with EAK16-I peptide plus methionine and 2% ethanol were administrated intravenously, significantly reducing severity of lung injury.	Methionine	41-51	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
27586187-9	2016	PP2 formulated with EAK16-I peptide plus methionine and 2% ethanol were administrated intravenously, significantly reducing severity of lung injury.	Ethanol	59-66	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
27711707-3	2016	APMO/PP2 PAs display an overall mean absolute error of 0.68 kcal mol-1 with respect to experimental data.	Aminosalicylic Acid	9-12	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	5-8
26363223-5	2015	In vitro, exposure of HK-2 cells (a human RTEC line), to high glucose (HG) promoted phosphorylation of c-Src and p38 MAPK, and subsequently, as revealed by western blotting, TUNEL assay and flow cytometry, increased cell death, which can be inhibited by PP2.	Glucose	62-69	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	254-257
27526105-8	2016	In vitro inhibition of Src signaling using 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2) resulted in reduced anchorage-independent and -dependent growth, and in three-dimensional cell culture models PP2 disrupted aggregate formation in Src-pY416-positive but not in Src-pY416-negative cell lines.	4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine	43-112	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	114-117
27256015-2	2016	PYR1/PYL/RCAR proteins are ABA receptors that function by inhibiting PP2Cs to activate SnRK2s, resulting in phosphorylation of ABFs and other effectors of ABA response pathways.	Abscisic Acid	27-30	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	69-72
26815118-9	2016	Finally, neither STK301831 nor NOX1 silencing impaired Src phosphorylation, but PP2 blocked early ROS production, showing that Src is involved in NOX1 activation.	Reactive Oxygen Species	98-101	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	80-83
26645814-1	2016	The purpose of this study is to investigate postprandial 1-h (PP1) and 2-h (PP2) blood glucose measurements" correlation with adverse perinatal outcomes.	Blood Glucose	81-94	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	76-79
26645814-6	2016	PP2 plasma glucose measurements (but not PP1) were positively correlated with fetal macrosomia.	Glucose	11-18	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
26899541-12	2016	Decreased insulin resistance and suspected enhanced glucose stimulated insulin secretion decreasing PP2 seem to contribute improved glucose homeostasis after PD.	Glucose	52-59	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	100-103
25289715-7	2015	During the postsupplementation session PP2 and PP3 increased in creatine supplemented group (from 642.7+-148.6 to 825.1+-205.2 in PP2 and from 522.9+-117.5 to 683.0+-148.0 in PP3, respectively).	Creatine	64-72	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	39-42
25289715-7	2015	During the postsupplementation session PP2 and PP3 increased in creatine supplemented group (from 642.7+-148.6 to 825.1+-205.2 in PP2 and from 522.9+-117.5 to 683.0+-148.0 in PP3, respectively).	Creatine	64-72	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	130-133
25609086-3	2015	In an effort to identify novel substrates of B56-containing PP2As, we found that B56-containing PP2As and Akt act antagonistically to control reversible phosphorylation of Fam13a on Ser-322.	Serine	182-185	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	60-63
26375462-10	2015	Furthermore, only NBCe1 was significantly phosphorylated and translocated by NH4Cl, which was inhibited by PP2.	Ammonium Chloride	77-82	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	107-110
25082669-0	2015	Activation of the aryl hydrocarbon receptor by the widely used Src family kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2).	4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine	91-160	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	162-165
25082669-2	2015	4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine (PP2) is a widely used compound to block the activity of Src family kinases, the major group of non-receptor tyrosine kinases, which trigger multiple cellular signaling pathways.	4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine	0-69	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	71-74
25761747-6	2015	The ability of CCK-8 to cause EGFR tyrosine phosphorylation was blocked by CI-988, gefitinib (EGFR tyrosine kinase inhibitor), PP2 (Src inhibitor), GM6001 (matrix metalloprotease inhibitor), and tiron (superoxide scavenger).	Tyrosine	35-43	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	127-130
26056051-5	2015	In MOR-GFP expressing HEK293 cells, treatment with either arrestin siRNA, the Src family kinase inhibitor PP2, or the protein kinase C (PKC) inhibitor Go6976 indicated that morphine activated JNK2 through an arrestin-independent Src- and PKC-dependent mechanism, whereas fentanyl activated JNK2 through a Src-GRK3/arrestin-2-dependent and PKC-independent mechanism.	Morphine	173-181	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	106-109
26096914-9	2015	The alpha-adrenergic agonist phenylephrine (PE) increased tissue stress and stiffness, both attenuated by cytochalasin D (CytoD) and PP2, inhibitors of actin polymerization and Src activity, respectively.	Phenylephrine	29-42	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	133-136
26096914-9	2015	The alpha-adrenergic agonist phenylephrine (PE) increased tissue stress and stiffness, both attenuated by cytochalasin D (CytoD) and PP2, inhibitors of actin polymerization and Src activity, respectively.	Phenylephrine	44-46	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	133-136
25817574-0	2015	GW5074 and PP2 kinase inhibitors implicate nontraditional c-Raf and Lyn function as drivers of retinoic acid-induced maturation.	Tretinoin	95-108	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	11-14
25817574-3	2015	In this study GW5074 (a c-Raf inhibitor) and PP2 (a Src-family kinase inhibitor) enhanced RA-induced maturation of t(15;17)-negative myeloblastic leukemia cells and rescued response in RA-resistant cells.	Tretinoin	90-92	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	45-48
27096001-9	2015	Our results also indicate that the stimulation of tyrosine-phosphorylation of Ric-8A by Galpha13 is partially sensitive to inhibitors of Src-family of kinases, namely PP2 and SI.	Tyrosine	50-58	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	167-170
26132234-10	2015	A univariable analysis revealed that only the PP2 value was associated with the Mini-Mental State Examination (MMSE) score, and multivariable analysis revealed that a high SD and/or CV for PP2 glucose were associated with low scores on the Rey Complex Figure Copy test and/or the Verbal Learning Test.	Glucose	193-200	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	189-192
25838144-2	2015	These novel inhibitors were designed based on the structure of Darunavir with modification on the P2 and P2" position.	Darunavir	63-72	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	98-107
25609086-7	2015	B56-containing PP2As dephosphorylate phospho-Ser-322 and promote nuclear localization of Fam13a.	Serine	45-48	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	15-18
25143807-8	2014	Interestingly, Cyto B and PP2, a Src inhibitor, enhanced the phagocytic uptake of fluorescein isothiocyanate (FITC)-dextran.	Fluorescein-5-isothiocyanate	82-108	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	26-29
25658311-0	2015	PP2 prevents isoproterenol stimulation of cardiac pacemaker activity.	Isoproterenol	13-26	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
25658311-2	2015	We report here that a widely used selective inhibitor of Src tyrosine kinases, PP2, can inhibit and prevent isoproterenol stimulation of cardiac pacemaker activity.	Isoproterenol	108-121	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	79-82
25658311-3	2015	In dissected rat sinus node, PP2 inhibited and prevented isoproterenol stimulation of spontaneous beating rate.	Isoproterenol	57-70	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	29-32
25658311-4	2015	In isolated sinus node myocytes, PP2 suppressed the hyperpolarization-activated "funny" current (If) by negatively shifting the activation curve and decelerating activation kinetics, associated with decreased cell surface expression and reduced tyrosine phosphorylation of hyperpolarization-activated cyclic nucleotide-modulated channel 4 (HCN4) channel proteins.	Tyrosine	245-253	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	33-36
25658311-4	2015	In isolated sinus node myocytes, PP2 suppressed the hyperpolarization-activated "funny" current (If) by negatively shifting the activation curve and decelerating activation kinetics, associated with decreased cell surface expression and reduced tyrosine phosphorylation of hyperpolarization-activated cyclic nucleotide-modulated channel 4 (HCN4) channel proteins.	Nucleotides, Cyclic	301-318	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	33-36
25658311-5	2015	In human embryonic kidney 293 cells overexpressing recombinant human HCN4 channels, PP2 reversed isoproterenol stimulation of HCN4 and inhibited HCN4-573x, a cAMP-insensitive human HCN4 mutant.	Isoproterenol	97-110	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	84-87
25658311-5	2015	In human embryonic kidney 293 cells overexpressing recombinant human HCN4 channels, PP2 reversed isoproterenol stimulation of HCN4 and inhibited HCN4-573x, a cAMP-insensitive human HCN4 mutant.	Cyclic AMP	158-162	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	84-87
25277753-2	2015	beta-Glucan triggered a prolonged phosphorylation of Src family kinases and Syk that were suppressed by the Src family inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3, 4-d] pyrimidine (PP2) and a novel Syk inhibitor, PRT-060318, respectively.	beta-Glucans	0-11	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	196-199
25657738-3	2014	Therefore, we hypothesized that a decrease in SFK activation by a long-term treatment with 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyramidine (PP2), a selective SFK inhibitor, after spinal cord contusion with the New York University (NYU) impactor device would generate a permissive environment that improves axonal sprouting and/or behavioral activity.	4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyramidine	91-154	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	156-159
25505610-7	2014	The signaling properties of COA-Cl showed significant similarities to those of sphingosine 1-phosphate, an endogenous S1P1 ligand, in that both induced responses sensitive to pertussis toxin (Galpha i/o inhibitor), 1,2-bis(2-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid tetrakis (acetoxymethyl ester) (BAPTA-AM), (calcium chelator), and PP2 (c-Src tyrosine kinase inhibitor).	coa-cl	28-34	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	339-342
25505610-7	2014	The signaling properties of COA-Cl showed significant similarities to those of sphingosine 1-phosphate, an endogenous S1P1 ligand, in that both induced responses sensitive to pertussis toxin (Galpha i/o inhibitor), 1,2-bis(2-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid tetrakis (acetoxymethyl ester) (BAPTA-AM), (calcium chelator), and PP2 (c-Src tyrosine kinase inhibitor).	sphingosine 1-phosphate	79-102	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	339-342
24953245-0	2014	Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.	Tretinoin	125-148	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	28-31
24953245-0	2014	Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.	Arsenic Trioxide	153-169	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	28-31
24953245-3	2014	We demonstrated SFK (Src family kinase) inhibitor PP2-enhanced APL cell differentiation when combined with either ATRA or ATO with difference in activation of RA-induced genes.	Tretinoin	114-118	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	50-53
24953245-3	2014	We demonstrated SFK (Src family kinase) inhibitor PP2-enhanced APL cell differentiation when combined with either ATRA or ATO with difference in activation of RA-induced genes.	Arsenic Trioxide	122-125	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	50-53
25745428-7	2015	PYLs inhibited PP2Cs in both the presence and absence of ABA and activated SnRK2s.	pyrrolysine	0-4	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	15-18
25277753-2	2015	beta-Glucan triggered a prolonged phosphorylation of Src family kinases and Syk that were suppressed by the Src family inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3, 4-d] pyrimidine (PP2) and a novel Syk inhibitor, PRT-060318, respectively.	AG 1879	129-194	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	196-199
25277753-2	2015	beta-Glucan triggered a prolonged phosphorylation of Src family kinases and Syk that were suppressed by the Src family inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3, 4-d] pyrimidine (PP2) and a novel Syk inhibitor, PRT-060318, respectively.	2-(2-aminocyclohexylamino)-4-(m-tolylamino)pyrimidine-5-carboxamide	228-238	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	196-199
25277753-3	2015	PP2 and PRT-060318 also inhibited beta-glucan-induced NET formation and reactive oxygen species (ROS) generation, suggesting that both responses are triggered by a Src/Syk-regulated signaling pathway.	beta-Glucans	34-45	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
25277753-3	2015	PP2 and PRT-060318 also inhibited beta-glucan-induced NET formation and reactive oxygen species (ROS) generation, suggesting that both responses are triggered by a Src/Syk-regulated signaling pathway.	Reactive Oxygen Species	72-95	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
25277753-3	2015	PP2 and PRT-060318 also inhibited beta-glucan-induced NET formation and reactive oxygen species (ROS) generation, suggesting that both responses are triggered by a Src/Syk-regulated signaling pathway.	Reactive Oxygen Species	97-100	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
25657827-6	2014	Inhibitors of VEGFR-2 (SU1498) or Src (PP2) significantly diminished UTP-induced Rac1 activation, tyrosine phosphorylation of p120 catenin and VE-cadherin, and association of the P2Y2R with VE-cadherin and p120 catenin with vav2.	Uridine Triphosphate	69-72	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	39-42
25657827-6	2014	Inhibitors of VEGFR-2 (SU1498) or Src (PP2) significantly diminished UTP-induced Rac1 activation, tyrosine phosphorylation of p120 catenin and VE-cadherin, and association of the P2Y2R with VE-cadherin and p120 catenin with vav2.	Tyrosine	98-106	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	39-42
24975826-8	2014	TRPA1 became repressed in SH-SY5Y clones but was rapidly rescued by Src-family inhibitor PP2 [4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine].	AG 1879	94-157	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	89-92
25143807-8	2014	Interestingly, Cyto B and PP2, a Src inhibitor, enhanced the phagocytic uptake of fluorescein isothiocyanate (FITC)-dextran.	fluorescein isothiocyanate dextran	110-123	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	26-29
24566462-3	2014	We report here that a widely used selective inhibitor of Src tyrosine kinases, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2), can inhibit and prevent beta-adrenergic stimulation of cardiac pacemaker activity.	AG 1879	79-142	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	144-147
24566462-4	2014	First, in dissected rat sinus node, PP2 inhibited and prevented the isoproterenol-induced increase of spontaneous beating rate.	Isoproterenol	68-81	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	36-39
24566462-6	2014	Third, in isolated rat sinus node myocytes, PP2 decreased the Src kinase activity, the cell surface expression, and tyrosine phosphorylation of hyperpolarization-activated, cyclic nucleotide-modulated channel 4 (HCN4) channel proteins.	Tyrosine	116-124	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	44-47
24566462-6	2014	Third, in isolated rat sinus node myocytes, PP2 decreased the Src kinase activity, the cell surface expression, and tyrosine phosphorylation of hyperpolarization-activated, cyclic nucleotide-modulated channel 4 (HCN4) channel proteins.	Nucleotides, Cyclic	173-190	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	44-47
24566462-7	2014	Finally, in human embryonic kidney 293 cells overexpressing recombinant human HCN4 channels, PP2 reversed the enhancement of HCN4 channels by isoproterenol and inhibited 573x, a cyclic adenosine momophosphate-insensitive human HCN4 mutant.	Isoproterenol	142-155	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	93-96
24566462-7	2014	Finally, in human embryonic kidney 293 cells overexpressing recombinant human HCN4 channels, PP2 reversed the enhancement of HCN4 channels by isoproterenol and inhibited 573x, a cyclic adenosine momophosphate-insensitive human HCN4 mutant.	cyclic adenosine momophosphate	178-208	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	93-96
22505597-6	2014	Moreover, the Src inhibitor PP2 reduced the phosphorylation of Src and activation of PI3K/Akt, which was comparable with FNQ treatment.	furano-1,2-naphthoquinone	121-124	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	28-31
24578342-3	2014	The Gi2-coupled delta-opioid receptor agonist d-penicillamine (2,5)-enkephalin (DPDPE) activated cSrc, stimulated tyrosine phosphorylation of Galphai2, and induced regulator of G protein signaling 12 (RGS12) association; all three events were blocked by PI 3-kinase (LY294002) and cSrc (PP2) inhibitors and by expression of the COOH-terminal sequence of GRK2-(495-689), a Gbetagamma-scavenging peptide.	Penicillamine	46-61	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	287-290
24578342-3	2014	The Gi2-coupled delta-opioid receptor agonist d-penicillamine (2,5)-enkephalin (DPDPE) activated cSrc, stimulated tyrosine phosphorylation of Galphai2, and induced regulator of G protein signaling 12 (RGS12) association; all three events were blocked by PI 3-kinase (LY294002) and cSrc (PP2) inhibitors and by expression of the COOH-terminal sequence of GRK2-(495-689), a Gbetagamma-scavenging peptide.	2,5)-enkephalin	63-78	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	287-290
24578342-4	2014	Inhibition of forskolin-stimulated cAMP and muscle relaxation by DPDPE was augmented by PP2, LY294002, and a selective PI 3-kinase-gamma inhibitor, AS-605420.	Colforsin	14-23	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	88-91
24578342-4	2014	Inhibition of forskolin-stimulated cAMP and muscle relaxation by DPDPE was augmented by PP2, LY294002, and a selective PI 3-kinase-gamma inhibitor, AS-605420.	Cyclic AMP	35-39	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	88-91
24578342-7	2014	Inhibition of cAMP and muscle relaxation was greatly increased by AS-605240 and PP2.	Cyclic AMP	14-18	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	80-83
24037816-4	2014	Ouabain-sensitive (86) Rb uptake was reduced by >35% in cultured NPE cells exposed to SNP (100 microM) or exogenously added cGMP (8-Br-cGMP) (100 microM) and the SFK inhibitor PP2 (10 microM) prevented the response.	Ouabain	0-7	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	179-182
24424050-5	2014	The PKC inhibitor calphostin C (CalC) and the c-Src inhibitor (4 amino 5 (4 chlorophenyl) 7 (t butyl)pyrazolo[3,4 d]pyrimidine [PP2]) suppressed TACE/ADAM17 enzyme activity, whereas these inhibitors did not affect Tace/Adam17 mRNA expression.	AG 1879	63-126	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	128-131
24424050-7	2014	Either CalC or PP2 suppressed EGFR downstream signaling pathway (MAPK3/1) in these ovarian cell types and reduced cumulus expansion, meiotic maturation of oocytes, and progesterone production.	Progesterone	168-180	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	15-18
24727858-8	2014	Our data showed that BPAF-induced transcription could be significantly blocked by PP2, PD98059 and U0126, suggesting activation of ERK1/2 was also required to regulate endogenous transcription.	4,4'-hexafluorisopropylidene diphenol	21-25	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	82-85
24037816-4	2014	Ouabain-sensitive (86) Rb uptake was reduced by >35% in cultured NPE cells exposed to SNP (100 microM) or exogenously added cGMP (8-Br-cGMP) (100 microM) and the SFK inhibitor PP2 (10 microM) prevented the response.	Rubidium	23-25	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	179-182
24037816-4	2014	Ouabain-sensitive (86) Rb uptake was reduced by >35% in cultured NPE cells exposed to SNP (100 microM) or exogenously added cGMP (8-Br-cGMP) (100 microM) and the SFK inhibitor PP2 (10 microM) prevented the response.	Cyclic GMP	127-131	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	179-182
24037816-4	2014	Ouabain-sensitive (86) Rb uptake was reduced by >35% in cultured NPE cells exposed to SNP (100 microM) or exogenously added cGMP (8-Br-cGMP) (100 microM) and the SFK inhibitor PP2 (10 microM) prevented the response.	8-bromoguanosino-3',5'-cyclic monophosphorothioate	133-142	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	179-182
24037816-6	2014	Tyrosine-10 phosphorylation of Na,K-ATPase alpha1 subunit was detected in SNP and L-arginine-treated cells and the response prevented by PP2.	Tyrosine	0-8	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	137-140
24037816-6	2014	Tyrosine-10 phosphorylation of Na,K-ATPase alpha1 subunit was detected in SNP and L-arginine-treated cells and the response prevented by PP2.	Arginine	82-92	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	137-140
24037816-8	2014	Cells exposed to 8-Br-cGMP displayed SFK activation (phosphorylation) and inhibition of both ouabain-sensitive (86) Rb uptake and Na,K-ATPase activity that was prevented by PP2.	8-bromoguanosino-3',5'-cyclic monophosphorothioate	17-26	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	173-176
24037816-8	2014	Cells exposed to 8-Br-cGMP displayed SFK activation (phosphorylation) and inhibition of both ouabain-sensitive (86) Rb uptake and Na,K-ATPase activity that was prevented by PP2.	Rubidium	116-118	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	173-176
24037816-10	2014	SNP and 8-Br-cGMP also increased phosphorylation of ERK1/2 and p38 MAPK and the response prevented by PP2.	8-bromoguanosino-3',5'-cyclic monophosphorothioate	8-17	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	102-105
23845719-7	2014	FAK inhibition (siRNA, PF-228 and PP2) in PAH-PASMCs induced a fivefold increase in apoptosis (percentage of terminal deoxynucleotidyl transferase dUTP nick end labelling), a 2.5-fold decrease in proliferation (%Ki67), an 18% decrease in cell migration (colorimetric assay) and a 50% decrease in cell invasion (wound healing).	pah-pasmcs	42-52	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	34-37
23845719-7	2014	FAK inhibition (siRNA, PF-228 and PP2) in PAH-PASMCs induced a fivefold increase in apoptosis (percentage of terminal deoxynucleotidyl transferase dUTP nick end labelling), a 2.5-fold decrease in proliferation (%Ki67), an 18% decrease in cell migration (colorimetric assay) and a 50% decrease in cell invasion (wound healing).	deoxyuridine triphosphate	147-151	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	34-37
23673518-4	2013	CdCl2-induced phosphorylation of FOXO3a was markedly suppressed by the epidermal growth factor receptor inhibitor, AG1478 (1 muM), the Ca(2+)/calmodulin-dependent kinase II inhibitor, KN-93 (10 muM), and the Src inhibitor, PP2 (10 muM), but only partially suppressed by the insulin-like growth factor-1 receptor inhibitor, PPP (2.5 muM).	Cadmium Chloride	0-5	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	223-226
24392464-10	2014	The aim of this study was to test the hypothesis that the combined treatment with hypothermia and PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), a highly selective inhibitor of Src kinase, immediately after the hypoxic insult may augment the beneficial effect of hypothermia on hypoxia/ischemia- induced neuronal necrosis.	AG 1879	103-166	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	98-101
24167135-4	2013	RESULTS: MTT assay showed that the survive rate of Hs578T cells treated with PP2 (1   8 mumol/L) was 98% +- 3%   94 % +- 4%.	monooxyethylene trimethylolpropane tristearate	9-12	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	77-80
23677800-6	2013	PP2, an SFK inhibitor, prevented the DIDS responses.	4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid	37-41	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
23677800-8	2013	PP2-sensitive Na-K-ATPase activity inhibition, (86)Rb uptake suppression, and SFK activation were observed when a similar reduction of pHi was imposed by low-pH medium or an ammonium chloride withdrawal maneuver.	Ammonium Chloride	174-191	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
23677800-9	2013	PP2 and the ERK inhibitor U0126 prevented robust ERK1/2 activation in cells exposed to DIDS or subjected to pHi reduction, but U0126 did not prevent SFK activation or the Na-K-ATPase activity response.	4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid	87-91	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
22575628-0	2013	SRC kinase family inhibitor PP2 promotes DMSO-induced cardiac differentiation of P19 cells and inhibits proliferation.	Dimethyl Sulfoxide	41-45	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	28-31
22575628-10	2013	However PP2 supplementation dramatically increases DMSO induced cardiac differentiation than DMSO alone.	Dimethyl Sulfoxide	51-55	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	8-11
22575628-10	2013	However PP2 supplementation dramatically increases DMSO induced cardiac differentiation than DMSO alone.	Dimethyl Sulfoxide	93-97	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	8-11
22575628-12	2013	CONCLUSION: PP2 alone cannot substitute DMSO to induce cardiac differentiation, however, PP2 supplementation drastically promotes DMSO-induced cardiac differentiation of P19 cells.	Dimethyl Sulfoxide	130-134	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	89-92
24167135-8	2013	And the expression ratio of Src kinase/beta-actin of Hs578T cells treated with 8 mumol/L PP2 for 6,12 and 24h was 0.82 +- 0.03,0.66 +- 0.08 and 0.59 +-0.09, which were all inhibited significantly compared to control group (P<0.01).	9-(3-hydroxy-2-phosphonomethoxypropyl)guanine	106-109	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	89-92
23864846-0	2013	Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line.	Tretinoin	57-80	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	28-31
23703528-5	2013	In Caco-2/BBe cells, carbachol (CCh) decreased NHE3 activity by ~40%, an effect abolished with the c-Src inhibitor PP2.	Carbachol	21-30	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	115-118
23703528-5	2013	In Caco-2/BBe cells, carbachol (CCh) decreased NHE3 activity by ~40%, an effect abolished with the c-Src inhibitor PP2.	Carbachol	32-35	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	115-118
23280824-9	2013	PP2 decreased the levels of IL-1beta, c-Src/inhibitory kappa B kinase complex formed and prostaglandin E2 produced in the dorsal root ganglia (DRG) ipsilateral to the inflamed paw, while SSG increased the levels of these parameters.	Dinoprostone	89-105	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
23900414-7	2013	Further studies using the SRC-specific inhibitor PP2 showed that SRC inhibition upon treatment with the inhibitor Ki11502 is responsible for the observed effects of Ki11502 in SW480 and DLD-1 CRC cells.	Ki11502	114-121	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	49-52
23900414-7	2013	Further studies using the SRC-specific inhibitor PP2 showed that SRC inhibition upon treatment with the inhibitor Ki11502 is responsible for the observed effects of Ki11502 in SW480 and DLD-1 CRC cells.	Ki11502	165-172	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	49-52
23864846-0	2013	Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line.	Arsenic Trioxide	84-100	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	28-31
23864846-4	2013	In addition, we attempted to determine the difference in retinoic acid-induced gene expression between cells treated with PP2 in combination with ATRA and in combination with ATO.	Tretinoin	57-70	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	122-125
23864846-5	2013	RESULTS: SFK inhibitor PP2 induced significant enhancement of ATRA- or ATO-induced differentiation of NB4 cells.	Tretinoin	62-66	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	23-26
23864846-5	2013	RESULTS: SFK inhibitor PP2 induced significant enhancement of ATRA- or ATO-induced differentiation of NB4 cells.	Arsenic Trioxide	71-74	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	23-26
23864846-6	2013	A significantly stronger synergistic effect was observed when PP2 was combined with ATRA than when combined with ATO.	Arsenic Trioxide	113-116	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	62-65
23864846-12	2013	Intercellular adhesion molecule-1 expression showed a significant increase in cells treated with PP2 in combination with ATRA, whereas cathepsin D expression showed a significant increase in cells treated with PP2 in combination with ATO.	Tretinoin	121-125	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	97-100
23864846-13	2013	CONCLUSION: Our data showed that SFK inhibitor PP2 enhanced acute promyelocytic leukemia cell differentiation when combined with either ATRA or ATO with difference in activation of retinoic acid-induced genes.	Tretinoin	136-140	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	47-50
23864846-13	2013	CONCLUSION: Our data showed that SFK inhibitor PP2 enhanced acute promyelocytic leukemia cell differentiation when combined with either ATRA or ATO with difference in activation of retinoic acid-induced genes.	Arsenic Trioxide	144-147	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	47-50
23864846-13	2013	CONCLUSION: Our data showed that SFK inhibitor PP2 enhanced acute promyelocytic leukemia cell differentiation when combined with either ATRA or ATO with difference in activation of retinoic acid-induced genes.	Tretinoin	181-194	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	47-50
23496660-4	2013	We found that the hSKCa1 current was inhibited by the broad-spectrum PTK inhibitor genistein, the selective EGFR (epidermal growth factor receptor) kinase inhibitors T25 (tyrphostin 25) and AG556 (tyrphostin AG 556), but not by the Src-family kinases inhibitor PP2.	AG 556	190-195	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	261-264
23305708-7	2013	Barrier-disruptive effects of PGPC were abrogated by reactive oxygen species (ROS) inhibitor, N-acetyl cysteine, or Src kinase inhibitor, PP-2.	1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine	30-34	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	116-142
23718910-7	2013	PP2, a c-Src inhibitor, also inhibited the tyrosine phosphorylation of IkappaB-alpha and NF-kappaB p65 nuclear translocation induced by high glucose.	Tyrosine	43-51	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
23718910-7	2013	PP2, a c-Src inhibitor, also inhibited the tyrosine phosphorylation of IkappaB-alpha and NF-kappaB p65 nuclear translocation induced by high glucose.	Glucose	141-148	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
23124605-9	2013	The Src family kinase inhibitor PP2 blocked injury-induced tyrosine phosphorylation.	Tyrosine	59-67	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	32-35
23697410-7	2013	Results presented in this work suggest that the APMO/PP2 approach is a promising tool for studying proton acid/base properties.	proton acid	99-110	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	53-56
23404499-3	2013	The leucine-facilitated insulin-induced phosphorylation of Akt at residue 473 was not affected by knocking down the key component of mTORC1 or -2 complexes but was blocked by inhibition of c-Src (PP2), PI3K (LY294002), Galphai protein (pertussis toxin or siRNA against Galphai1 gene, or beta-arrestin 2 (siRNA)).	Leucine	4-11	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	196-199
23422267-8	2013	Treatment with dasatinib or with a specific inhibitor of Src kinases such as PP2 suppressed constitutive LYN activation and increased in vitro spontaneous apoptosis of primary MCL cells.	Dasatinib	15-24	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	77-80
23246833-6	2013	Treatment with TO-901317, pertussis toxin, PP2, and LY294002 resulted not only in attenuated transcription of TNF-alpha induced by 27OHChol and 7alphaOHChol, but also secretion of TNF-alpha enhanced by 27OHChol.	27ohchol	131-139	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	43-46
23246833-6	2013	Treatment with TO-901317, pertussis toxin, PP2, and LY294002 resulted not only in attenuated transcription of TNF-alpha induced by 27OHChol and 7alphaOHChol, but also secretion of TNF-alpha enhanced by 27OHChol.	7alphaohchol	144-156	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	43-46
23246833-6	2013	Treatment with TO-901317, pertussis toxin, PP2, and LY294002 resulted not only in attenuated transcription of TNF-alpha induced by 27OHChol and 7alphaOHChol, but also secretion of TNF-alpha enhanced by 27OHChol.	27ohchol	202-210	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	43-46
22726910-4	2013	Members of a subclass of plant PP2Cs counteract mitogen-activated protein kinase pathways, whereas members of other subfamilies function as co-receptors for the phytohormone abscisic acid.	Abscisic Acid	174-187	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	31-34
23178716-4	2013	As2O3 activates Src(Y416) whose activity (inhibited by PP2) modulates EGFR activation, its interaction with Shc/Grb2, and p-AKT.	Arsenic Trioxide	0-5	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	55-58
23178716-4	2013	As2O3 activates Src(Y416) whose activity (inhibited by PP2) modulates EGFR activation, its interaction with Shc/Grb2, and p-AKT.	y416	20-24	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	55-58
22287273-4	2012	Furthermore, Src inhibition via morpholino knockdown of Src or by the small molecule inhibitor PP2 prevents phenylephrine-induced adhesion protein phosphorylation, markedly slows the tissue"s ability to contract, and decreases steady state contractile force amplitude.	Phenylephrine	108-121	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	95-98
22658320-2	2012	A specific c-Src inhibitor, 4-amino-5-(4-chlorophenyl)-7(t-butyl)pyrazolo[3,4-d]pyrinidine (PP2), was utilised to block c-Src activity to identify targeted vulnerabilities affected by ER and HER2 in a panel of breast cancer cell lines.	4-amino-5-(4-chlorophenyl)-7(t-butyl)pyrazolo[3,4-d]pyrinidine	28-90	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	92-95
23066026-7	2012	Moreover, A23187-induced thromboxane A(2) synthesis, platelet aggregation, and secretion were inhibited by preincubation of platelets with a selective SFK inhibitor, PP2.	Calcimycin	10-16	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	166-169
23066026-7	2012	Moreover, A23187-induced thromboxane A(2) synthesis, platelet aggregation, and secretion were inhibited by preincubation of platelets with a selective SFK inhibitor, PP2.	thromboxane a	25-38	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	166-169
23554907-0	2013	The Src-family kinase inhibitor PP2 rescues inducible differentiation events in emergent retinoic acid-resistant myeloblastic leukemia cells.	Tretinoin	89-102	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	32-35
22544307-5	2012	Differential blocking of Src kinase family members (despite c-Src) by PP2 increased the activity of c-Src and the tyrosine phosphorylation of PTPIP51 at position 176, which is the substrate of c-Src kinase.	Tyrosine	114-122	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	70-73
22786868-0	2012	The HIV-1 protease inhibitor nelfinavir activates PP2 and inhibits MAPK signaling in macrophages: a pathway to reduce inflammation.	Nelfinavir	29-39	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	50-53
22786868-6	2012	Inhibition of PP2 with okadaic acid blocked the anti-inflammatory effect of NFV, whereas the PP1 inhibitor calyculin A failed to counter the anti-inflammatory effects of NFV.	Okadaic Acid	23-35	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	14-17
22582758-8	2012	This disintegration of beta-catenin from alpha-catenin and the cell dispersal caused by LPA can be rescued by blocking SFK activity with the chemical inhibitor, PP2.	lysophosphatidic acid	88-91	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	161-164
22823520-3	2012	The Src family kinase inhibitor PP2 {amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo [3,4d] pyrimidine} exhibits significant reduction of respiration.	amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo [3,4d] pyrimidine	37-100	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	32-35
23031400-7	2012	However, PP2 inhibited formalin injury, induced persistent mechanical hyperalgesia, and reversed microglial phospho-p38 expression as well using immunohistostaining and Western blot at day 3 and 7 after injection.	Formaldehyde	23-31	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	9-12
22771325-11	2012	PP2, a specific-inhibitor of Src kinase, abolished the testosterone-induced phosphorylation of Akt and eNOS.	Testosterone	55-67	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
22182854-0	2012	Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.	Tretinoin	44-57	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	16-19
21920544-8	2012	RESULTS: Inhibition of src with PP2 but not PP3 partially blocked S-1-P-mediated cell migration.	sphingosine 1-phosphate	66-71	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	32-35
21920544-9	2012	S-1-P induced time-dependent activation of src, which was inhibited by PP2 and adenoviral DNsrc.	sphingosine 1-phosphate	0-5	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	71-74
22182854-6	2012	PP2 and dasatinib increased the ATRA-induced expression of Lyn and c-Raf (total and c-RafpS259) and their interaction.	Tretinoin	32-36	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
22302306-4	2012	The Src inhibitor PP2 and FAK siRNA inhibited GIT1 tyrosine phosphorylation and the increased association between GIT1 and FAK following stimulation with PDGF.	Tyrosine	51-59	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	18-21
22282267-6	2012	In addition, the Src kinase inhibitor PP2 markedly sensitized MLL-rearranged ALL cells otherwise resistant to prednisolone, via downregulation of S100A8 and S100A9, which allowed prednisolone-induced Ca(2+) fluxes to reach the mitochondria and trigger apoptosis.	Prednisolone	110-122	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	38-41
22282267-6	2012	In addition, the Src kinase inhibitor PP2 markedly sensitized MLL-rearranged ALL cells otherwise resistant to prednisolone, via downregulation of S100A8 and S100A9, which allowed prednisolone-induced Ca(2+) fluxes to reach the mitochondria and trigger apoptosis.	Prednisolone	179-191	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	38-41
22333592-6	2012	Notably, our SRC inhibitors proved to be more effective than the well-known SRC inhibitor PP2 [4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine] in BL cells.	4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]pyrimidine	95-164	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	90-93
22361730-8	2012	Both TCDD-induced ERK1/2 phosphorylation and cell proliferation were abolished by AhR small interfering RNA, AhR-specific inhibitor CH223191, Src kinase inhibitor PP2, neutralizing antibodies against matrix metalloproteinase 7, heparin-binding-EGF-like growth factor and EGFR, EGFR inhibitors (AG1478 and PD168393), and MEK1 inhibitor PD98059.	Polychlorinated Dibenzodioxins	5-9	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	163-166
21956166-11	2012	Using pharmacological inhibitors, we observed that carbachol inhibits oxalate transport through the M(3) muscarinic receptor and phospholipase C. Utilizing the Src inhibitor PP2 and phosphorylation studies, we found that the observed regulation downstream of PKC-delta is partially mediated by c-Src.	Carbachol	51-60	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	174-177
22198508-8	2012	Interestingly, orthovanadate also reversed the reduced tyrosine phosphorylation level of hKv4.3 channels by genistein, AG556, or PP2.	Vanadates	15-28	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	129-132
22198508-8	2012	Interestingly, orthovanadate also reversed the reduced tyrosine phosphorylation level of hKv4.3 channels by genistein, AG556, or PP2.	Tyrosine	55-63	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	129-132
22200849-7	2012	Treatment of Jurkat T cells with okadaic acid, an inhibitor of PP2, also inhibited the increase of JNK and p38 activity induced by PP4.	Okadaic Acid	33-45	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	63-66
22240023-3	2012	Here we demonstrate that nicotine-induced E-selectin transcription in human aortic endothelial cells (HAECs) could be significantly blocked by alpha7-nAChR subunit inhibitor, alpha-BT, Src-kinase inhibitor, PP2, or siRNAs against Src or beta-Arrestin-1 (beta-Arr1).	Nicotine	25-33	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	207-210
21764100-6	2011	However, during the second sampling campaign for PP2 (2008), the mercury removal achieved by the FGD was much lower (26%).	Mercury	65-72	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	49-52
21992875-5	2012	In support of this, alkali-resistant (32)P-labeled SERT was found in rat platelets, and Src-tyrosine kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4,d]pyrimidine (PP2) decreased platelet SERT function and expression.	Phosphorus-32	37-42	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	184-187
21992875-5	2012	In support of this, alkali-resistant (32)P-labeled SERT was found in rat platelets, and Src-tyrosine kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4,d]pyrimidine (PP2) decreased platelet SERT function and expression.	AG 1879	118-182	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	184-187
23082158-6	2012	We found that aggregation of TxA2 production and granule secretion by beta3Delta724 human platelets initiated by alphaIIb mediated outside-in signaling was inhibited by the Src family kinase inhibitor PP2 and the PI3K inhibitor wortmannin, respectively, but not by the MAPK inhibitor U0126.	Wortmannin	228-238	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	201-204
23082158-6	2012	We found that aggregation of TxA2 production and granule secretion by beta3Delta724 human platelets initiated by alphaIIb mediated outside-in signaling was inhibited by the Src family kinase inhibitor PP2 and the PI3K inhibitor wortmannin, respectively, but not by the MAPK inhibitor U0126.	U 0126	284-289	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	201-204
21968138-9	2011	These events were dependent on Src, Rho and Rock because their chemical inhibitors PP2, toxin A and Y27632, respectively, abrogated the effects of LPA.	lysophosphatidic acid	147-150	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	83-86
21940635-6	2011	Furthermore, we found that Rap1b was activated by platelet spreading on immobilized fibrinogen, a process that was not affected by P2Y(12) or TXA(2) receptor deficiency, but was inhibited by the selective Src inhibitor PP2, the PKC inhibitor Ro-31-8220, or the calcium chelator demethyl-1,2-bis(2-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid tetrakis.	Ro 31-8220	242-252	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	219-222
21940635-6	2011	Furthermore, we found that Rap1b was activated by platelet spreading on immobilized fibrinogen, a process that was not affected by P2Y(12) or TXA(2) receptor deficiency, but was inhibited by the selective Src inhibitor PP2, the PKC inhibitor Ro-31-8220, or the calcium chelator demethyl-1,2-bis(2-aminophenoxy)ethane-N,N,N",N"-tetraacetic acid tetrakis.	demethyl-1,2-bis(2-aminophenoxy)ethane-n,n,n",n"-tetraacetic acid tetrakis	278-352	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	219-222
21883956-5	2011	Dasatinib and PP2 bind to bone marrow kinase in the X chromosome in the ATP binding pocket and display similar binding modes to that observed in other Tec and Src protein kinases.	Adenosine Triphosphate	72-75	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	14-17
21748785-7	2011	Furthermore, CIB1-induced cell migration, as well as Erk1/2 activation, is dependent on PKC, Src family kinases as well as PI-3 kinase as it is inhibited by bisindolylmaleimide 1, PP2, and wortmannin, respectively, in a dose-dependent manner.	Wortmannin	189-199	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	180-183
21859709-8	2011	Interestingly, only Src inhibitor PP2 greatly sensitized the cells to GA-mediated apoptosis.	gambogic acid	70-72	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	34-37
22785470-5	2012	Inhibition of Src by PP2 resulted in decreases in insulin-stimulated glucose uptake and phosphorylation of Src at Tyr416 and Akt at Thr308 and Ser473.	Glucose	69-76	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	21-24
22505999-7	2012	Alternatively, treatment of MDA-MB-231 cells with the Src family kinase inhibitor PP2 reduced caveolin-1 phosphorylation on tyrosine-14 and cell migration.	Tyrosine	124-132	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	82-85
21764100-10	2011	Moreover in PP2 a significant proportion of the gaseous mercury reaching the FGD system remained in the aqueous phase (45%) in the 2007 sampling campaign while most of it escaped in 2008 (74%).	Mercury	56-63	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	12-15
21482955-4	2011	Renal interstitial cGMP-induced natriuresis was blocked by Src inhibitor PP2 (2.0+-0.4 versus 0.5+-0.01 muEq/g per minute; P<0.001).	Cyclic GMP	19-23	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	73-76
21606925-10	2011	ML-7 and PP2 (MLCK and Src kinase inhibitors) attenuated hydrogen peroxide-induced barrier dysfunction, tight junction disruption and reorganization of actin cytoskeleton.	Hydrogen Peroxide	57-74	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	9-12
21737448-10	2011	Osmotic stress induced a robust increase in tyrosine phosphorylation of occludin, which was attenuated by BAPTA, SP600125 (JNK inhibitor), or PP2.	Tyrosine	44-52	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	142-145
21712056-10	2011	The ability of BRS-3 to regulate EGFR transactivation in NCI-H1299-BRS-3 cells was reduced by AG1478 or gefitinib (EGFR tyrosine kinase inhibitors), GM6001 (matrix metalloprotease inhibitor), PP2 (Src inhibitor), N-acetylcysteine (anti-oxidant), Tiron (superoxide scavenger) and DPI (NADPH oxidase inhibitor).	RTKI cpd	94-100	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	192-195
21712056-10	2011	The ability of BRS-3 to regulate EGFR transactivation in NCI-H1299-BRS-3 cells was reduced by AG1478 or gefitinib (EGFR tyrosine kinase inhibitors), GM6001 (matrix metalloprotease inhibitor), PP2 (Src inhibitor), N-acetylcysteine (anti-oxidant), Tiron (superoxide scavenger) and DPI (NADPH oxidase inhibitor).	Gefitinib	104-113	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	192-195
21897118-3	2011	Erlotinib induced an arrest in the G 1 phase of the cell cycle that, in cells with constitutive SFK activation, could be recapitulated by chemical inhibition of SFKs with 3-(4-chlorophenyl)1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-alpha]pyrimidin-4-amine (PP2).	Erlotinib Hydrochloride	0-9	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	252-255
21897118-3	2011	Erlotinib induced an arrest in the G 1 phase of the cell cycle that, in cells with constitutive SFK activation, could be recapitulated by chemical inhibition of SFKs with 3-(4-chlorophenyl)1-(1,1-dimethylethyl)-1H-pyrazolo[3,4-alpha]pyrimidin-4-amine (PP2).	3-(4-chlorophenyl)1-(1,1-dimethylethyl)-1h-pyrazolo[3,4-alpha]pyrimidin-4-amine	171-250	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	252-255
21897118-5	2011	Notably, PP2 and the mTOR inhibitor rapamycin had a similar cell cycle-arresting activity to erlotinib, but neither of these compounds alone induced significant levels of cell death.	Erlotinib Hydrochloride	93-102	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	9-12
21516343-8	2011	The data show that administration of Src kinase inhibitor PP2 prevented the hypoxia-induced increased tyrosine phosphorylation of calmodulin (Tyr(99)) and tyrosine phosphorylation of CaM.kinase IV as well as the activity of CaM kinase IV and CREB phosphorylation at Ser(133).	Tyrosine	102-110	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	58-61
21516343-8	2011	The data show that administration of Src kinase inhibitor PP2 prevented the hypoxia-induced increased tyrosine phosphorylation of calmodulin (Tyr(99)) and tyrosine phosphorylation of CaM.kinase IV as well as the activity of CaM kinase IV and CREB phosphorylation at Ser(133).	Tyrosine	142-145	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	58-61
21516343-8	2011	The data show that administration of Src kinase inhibitor PP2 prevented the hypoxia-induced increased tyrosine phosphorylation of calmodulin (Tyr(99)) and tyrosine phosphorylation of CaM.kinase IV as well as the activity of CaM kinase IV and CREB phosphorylation at Ser(133).	Tyrosine	155-163	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	58-61
21516343-8	2011	The data show that administration of Src kinase inhibitor PP2 prevented the hypoxia-induced increased tyrosine phosphorylation of calmodulin (Tyr(99)) and tyrosine phosphorylation of CaM.kinase IV as well as the activity of CaM kinase IV and CREB phosphorylation at Ser(133).	Serine	266-269	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	58-61
21482955-11	2011	PP2 had no effect on renal hemodynamics but decreased both fractional excretion of Na(+) and lithium.	Lithium	93-100	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
21395548-4	2011	We show that PP2 and PP1 but not the more specific Src inhibitor SU6656 effectively relieved TGF-b1-induced growth arrest and p21(WAF1) induction, while basal growth was enhanced by PP2 and PP1, and suppressed by SU6656.	SU 6656	213-219	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	13-16
21505453-7	2011	Activation of VEGFR-2 and ErK(1/2) by 2-methylthio-ATP (2MeS-ATP) was blocked by pretreatment with the P2Y(1)-specific antagonist MRS2179, the proto-oncogene non-receptor tyrosine kinase (Src) inhibitor PP2 or the VEGFR-2 antagonist SU1498.	2-methylthio-ATP	38-54	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	203-206
21505453-7	2011	Activation of VEGFR-2 and ErK(1/2) by 2-methylthio-ATP (2MeS-ATP) was blocked by pretreatment with the P2Y(1)-specific antagonist MRS2179, the proto-oncogene non-receptor tyrosine kinase (Src) inhibitor PP2 or the VEGFR-2 antagonist SU1498.	Adenosine Triphosphate	51-54	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	203-206
21175263-11	2011	The ERK1/2 inhibitor PD98059, the PI3K/Akt inhibitor LY294002, and the c-Src inhibitor PP2 all enhanced TAM action.	Tamoxifen	104-107	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	87-90
21395548-7	2011	Interestingly, PP2 and PP1 strongly inhibited recombinant TbetaRI in an in vitro kinase assay, with PP1 being more potent and PP2 being nearly as potent as the established TbetaRI inhibitor SB431542.	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	190-198	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	126-129
20093046-7	2011	The non-receptor kinase Src co-immunoprecipitated with DDR1, and the Src inhibitor PP2 inhibited type I collagen-induced tyrosine phosphorylation of DDR1.	Tyrosine	121-129	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	83-86
21145940-7	2011	PP2, a c-Src specific inhibitor, suppressed both TCDD- and epidermal growth factor- (EGF) induced c-Src activation.	Polychlorinated Dibenzodioxins	49-53	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
21205633-9	2011	Pretreatment with a specific inhibitor for c-Src (4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine [PP2]) prevents Y845-HER1 and Y699-STAT5b phosphorylation.	AG 1879	50-114	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	116-119
21205633-12	2011	Pretreatment with PP2, AG1478, and 4,7-orthophenanthroline suppresses HCB-induced cell migration.	Hexachlorobenzene	70-73	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	18-21
20870010-9	2010	In contrast, the NGF-induced increase in capsaicin-evoked release of CGRP is blocked by the protein kinase C (PKC) inhibitor, BIM and the Src family kinases inhibitor, PP2.	Capsaicin	41-50	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	168-171
21127066-10	2011	Extracellular HSP90alpha induced EGFR phosphorylation at Tyr-1068, and this event was prevented by both the protein kinase Cdelta inhibitor, rottlerin, and the c-Src inhibitor, PP2.	Tyrosine	57-60	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	177-180
21052789-5	2011	MTT results showed that three compounds had different inhibitory effects on proliferation of two cervical cancer cells, HeLa and SiHa, and PP2 was most efficient in a time- and dose-dependent manner.	monooxyethylene trimethylolpropane tristearate	0-3	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	139-142
20189992-4	2010	Lyn knock-out or an isoform-nonselective SFK inhibitor, PP2, inhibited platelet secretion of both dense and alpha granules and the secretion-dependent platelet aggregation induced by thrombin, collagen, and thromboxane A(2).	thromboxane a	207-220	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	56-59
20631251-4	2010	Swelling-activated K(+) efflux was impaired by genistein and the Src kinase family inhibitor 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) and enhanced by the tyrosine phosphatase inhibitor mpV(pic).	Genistein	47-56	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	159-162
20631251-4	2010	Swelling-activated K(+) efflux was impaired by genistein and the Src kinase family inhibitor 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) and enhanced by the tyrosine phosphatase inhibitor mpV(pic).	pyrazolo(3,4-d)pyrimidine	131-157	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	159-162
20522022-3	2010	When UT-7/TPO was stimulated with the GPVI agonist convulxin, the [Ca2+]i (intracellular Ca2+) was elevated in a convulxin concentration-dependent manner, and [Ca2+]i elevation was blocked by pretreatment with the Src family kinase inhibitor PP2 and the phospholipase inhibitor U73122.	ut-7	5-9	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	242-245
20378826-7	2010	Promotion of cell migration by hydrogen peroxide was attenuated by LY294002 and PP2.	Hydrogen Peroxide	31-48	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	80-83
20705914-10	2010	Angiotensin II-induced Y168 phosphorylation was Src dependent, as evident by a significant reduction in Y168 phosphorylation by the Src family kinase inhibitor PP2 is 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).	y168	23-27	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	160-163
20705914-10	2010	Angiotensin II-induced Y168 phosphorylation was Src dependent, as evident by a significant reduction in Y168 phosphorylation by the Src family kinase inhibitor PP2 is 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).	y168	23-27	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	232-235
20705914-10	2010	Angiotensin II-induced Y168 phosphorylation was Src dependent, as evident by a significant reduction in Y168 phosphorylation by the Src family kinase inhibitor PP2 is 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).	y168	104-108	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	160-163
20705914-10	2010	Angiotensin II-induced Y168 phosphorylation was Src dependent, as evident by a significant reduction in Y168 phosphorylation by the Src family kinase inhibitor PP2 is 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).	y168	104-108	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	232-235
20705914-10	2010	Angiotensin II-induced Y168 phosphorylation was Src dependent, as evident by a significant reduction in Y168 phosphorylation by the Src family kinase inhibitor PP2 is 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).	AG 1879	167-230	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	160-163
20705914-10	2010	Angiotensin II-induced Y168 phosphorylation was Src dependent, as evident by a significant reduction in Y168 phosphorylation by the Src family kinase inhibitor PP2 is 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).	AG 1879	167-230	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	232-235
20705914-12	2010	Furthermore, Y232 phosphorylation increased approximately 3-fold in L341S-FRNK, which was less sensitive to PP2.	y232	13-17	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	108-111
20036247-3	2010	Pre-treatment of A10 VSMC with high glucose (26 mM) for 3 days, increased the levels of Gqalpha, G11alpha, PLCbeta-1 and PLCbeta-2 proteins which were restored to control levels by AG1478, an inhibitor of EGF-R, AG1295, an inhibitor of PDGF-R and PP2, an inhibitor of c-Src but not by PP3.	Glucose	36-43	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	247-250
20036247-4	2010	In addition, endothelin-1 (ET-1)-stimulated production of IP(3) that was enhanced by high glucose was also restored towards control levels by AG1478, AG1295 and PP2.	Inositol 1,4,5-Trisphosphate	58-63	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	161-164
20036247-5	2010	High glucose also increased the phosphorylation of EGF-R and PDGF-R which was abolished by AG1478, AG1295 and PP2.	Glucose	5-12	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	110-113
20541551-1	2010	We show that 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) induces apoptosis and down-regulates the expression of enoyl-CoA hydratase short chain 1 (ECHS1) and peroxiredoxin 3 (PRDX3) in human breast cancer MCF-7 cells.	AG 1879	13-76	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	78-81
20181660-3	2010	Similar to PKR inhibitors, Hck inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyramidine (PP2) suppressed p38 activation and p38-driven interleukin 8 (IL-8) expression in the U937 human monocyte cell line.	4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyramidine	41-104	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	106-109
20181660-4	2010	U937 cells stably transfected with a PKR antisense vector (U9K-A1) displayed marked reduction of DON-induced p38 activation and IL-8 expression as compared to cells transfected with empty vector (U9K-C2), with both responses being completely ablated by PP2.	deoxynivalenol	97-100	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	253-256
20181660-9	2010	Both 2-AP and PP2 inhibited DON-induced phosphorylation of p38 as well as two kinases, apoptosis signal-regulating kinase 1 and mitogen-activated protein kinase 3/6, known to be upstream of p38.	deoxynivalenol	28-31	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	14-17
20091677-7	2010	We found that PP2-containing Tat peptides are noncompetitive inhibitors of the core, interfering with the actions of PA28alphabeta activator.	pa28alphabeta	117-130	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	14-17
20189992-6	2010	Inhibitory effect of PP2 on platelet aggregation induced by thrombin and thromboxane A(2) were also reversed by supplementing ADP.	thromboxane a	73-86	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	21-24
20189992-6	2010	Inhibitory effect of PP2 on platelet aggregation induced by thrombin and thromboxane A(2) were also reversed by supplementing ADP.	Adenosine Diphosphate	126-129	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	21-24
19350555-11	2009	The promising effects of the inhibitors PP2 and PAO on osteoclast function suggest a therapeutic approach for patients with bone metastases and osteoporosis as an alternative to bisphosphonates.	Diphosphonates	178-193	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	40-43
20233211-6	2010	Effects of genistein on TRPC5 channels were mimicked by daidzein (100 microM), a genistein analogue inactive as a tyrosine kinase inhibitor, but not by known tyrosine kinase inhibitors herbimycin (2 microM), PP2 (20 microM) and lavendustin A (10 microM).	Genistein	11-20	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	208-211
20368025-7	2010	c-src siRNA and PP2 also showed the same effects, both of them decreased the NE-induced high activity of ROS, was 0.29 +/- 0.05, and 0.41 +/- 0.11, respectively, the MUC5AC protein in the c-src siRNA group and PP2 group were 0.38 +/- 0.09 and 0.48 +/- 0.08, MUC5AC mRNA level were 0.41 +/- 0.04 and 0.46 +/- 0.07, the Nox1 protein were 0.39 +/- 0.08 and 0.44 +/- 0.05, all P < 0.05, compared with single NE-treated group.	Reactive Oxygen Species	105-108	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	16-19
20368025-7	2010	c-src siRNA and PP2 also showed the same effects, both of them decreased the NE-induced high activity of ROS, was 0.29 +/- 0.05, and 0.41 +/- 0.11, respectively, the MUC5AC protein in the c-src siRNA group and PP2 group were 0.38 +/- 0.09 and 0.48 +/- 0.08, MUC5AC mRNA level were 0.41 +/- 0.04 and 0.46 +/- 0.07, the Nox1 protein were 0.39 +/- 0.08 and 0.44 +/- 0.05, all P < 0.05, compared with single NE-treated group.	Reactive Oxygen Species	105-108	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	210-213
19711372-6	2009	Inhibition of Src family kinases by PP2 attenuated the pH 6.6-induced tyrosine phosphorylation of E-cadherin and p120ctn, and prevented the loss of these proteins from AJs.	Tyrosine	70-78	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	36-39
19855047-7	2009	Our results provide evidence that PP2Cs are directly implicated in the ABA-dependent activation of OST1 and further suggest that the activation mechanism of AMPK/Snf1-related kinases through the inhibition of regulating PP2Cs is conserved from plants to human.	Abscisic Acid	71-74	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	34-37
19925780-10	2010	Prostaglandin D(2)-induced hBD-3 production, AP-1 activity, and c-Fos expression and phosphorylation were suppressed by U0126, PP2, and pertussis toxin, which are inhibitors of mitogen-activated protein kinase kinase (MEK), src, and G(i) proteins, respectively.	Prostaglandin D2	0-18	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	127-130
19925780-11	2010	The phosphorylation of extracellular signal-regulated kinase (ERK), downstream kinase of MEK, was induced by prostaglandin D(2), and suppressed by ramatroban, pertussis toxin, PP2, and U0126.	Prostaglandin D2	109-127	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	176-179
20508392-6	2010	On the other hand, PP2, a Src tyrosine kinase inhibitor, also inhibited AII-induced ERK1/2 and JNK activation, but its effect on ERK1/2 was less pronounced than that of olmesartan.	olmesartan	169-179	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	19-22
20508392-7	2010	Olmesartan, U0126 (an ERK1/2 inhibitor), SP600125 (a JNK inhibitor), and PP2 potently inhibited AII-induced RASMC migration.	rasmc	108-113	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	73-76
19457108-9	2009	Using PP2 to inhibit pp60(src) activation resulted in inhibition of increases in L1 tyrosine and extracellular receptor kinases 1/2 phosphorylation, and Y(1176) dephosphorylation.	Tyrosine	84-92	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	6-9
19556728-5	2009	PDGF-induced VSMC migration was significantly inhibited by PP2, a selective inhibitor of the Src kinase family, and was also significantly inhibited by the expression of kinase-inactive Src, suggesting that Src is required for VSMC migration.	vsmc	13-17	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	59-62
19356149-6	2009	Hydrogen peroxideinduced increase in co-immunoprecipitation of PP2A-Calpha with occludin was prevented by PP2, a Src kinase inhibitor.	hydrogen peroxideinduced	0-24	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	63-66
19138696-8	2009	This effect can be abrogated by administration of the c-Src inhibitor, PP2 which also restores sensitivity to tamoxifen.	Tamoxifen	110-119	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	71-74
19232361-11	2009	A combination of an Src inhibitor, PP2, and a Stat3 inhibitor, AG490, induced G2/M arrest and enhanced apoptosis compared with PP2 alone.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	63-68	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	127-130
19155632-5	2009	RESULTS: GSE-induced endothelium-dependent relaxations were abolished by N(G)-nitro-L-arginine (an eNOS inhibitor) and ODQ (a soluble guanylyl cyclase inhibitor), and they were reduced by MnTMPyP, polyethyleneglycol catalase, PP2 (an inhibitor of Src kinase) and wortmannin (an inhibitor of phosphoinositide 3-kinase).	1H-(1,2,3)oxadiazolo(4,4-a)quinoxalin-1-one	119-122	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	226-229
19718538-9	2009	Addition of either PP2 or PD98059 blocked the effects of ouabain on cell proliferation.	Ouabain	57-64	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	19-22
19146952-4	2009	Interestingly, the effects of vanadate on DLK are completely blocked by treatment with a Src family kinase inhibitor, PP2, or the expression of short hairpin RNA (shRNA) directed against Src.	Vanadates	30-38	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	118-121
19374863-2	2009	Unexpectedly, we found that, in U-937 monocytic cells, tyrphostin AG-126 augments the sensitivity of the corresponding genes to NO, in contrast to other protein tyrosine kinase inhibitors like genistein, PD 168393, PP2, and SU 11652.	Tyrphostins	55-65	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	215-218
19212674-7	2009	Both PP2 and dasatinib exerted synergistic growth inhibition of N417 cells in the combination with amrubicin.	amrubicin	99-108	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	5-8
19127349-4	2009	The loss in countering capacity of leptin on the ethanol-induced cytotoxicity was attained with Src kinase inhibitor, PP2, and EGFR kinase inhibitor, AG1478, as well as ERK inhibitor, PD98059.	Ethanol	49-56	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	118-121
18984583-6	2009	All three inhibitors are bound at the ATP-binding site, with PP2 and Dasatinib extending into a hydrophobic pocket deep in the substrate cleft, thereby providing a basis for the Src-specific inhibition.	Adenosine Triphosphate	38-41	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	61-64
18592268-10	2009	In DLD1 cells, the scattering activity induced by LPA was partially blocked by pretreatment with PP2 and PD98059, inhibitors of src kinase and MEK, respectively.	lysophosphatidic acid	50-53	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	97-100
18790786-11	2008	Inhibition of Akt or Src activation with wortmannin or PP2 blocked induction of VEGF-A by oxaliplatin in HT29 or RKO cells, respectively.	Oxaliplatin	90-101	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	55-58
18617000-5	2008	Immunoprecipitation and Western blot analysis demonstrated that membrane protein tyrosine phosphorylation of hERG channels was reduced by genistein, AG556, and PP2.	Tyrosine	81-89	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	160-163
18617000-6	2008	The reduction of hERG channel phosphorylation level by genistein, AG556 or PP2 was antagonized by orthovanadate.	Vanadates	98-111	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	75-78
18783823-5	2008	Moreover, we showed that PP2 [4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3, 4-d]pyrimidine], a Src family kinase (SFK) specific inhibitor, stimulates biochemical trophoblast cells differentiation while it inhibits cell adhesion and spreading without affecting cell fusion.	AG 1879	30-94	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	25-28
18783823-7	2008	This study shows that PP2 stimulates ERK1/2 and p38 activation after 24h of treatments and up to 3 days while it inhibits focal adhesion kinase (FAK) phosphorylation at many sites including Tyr-397, 407, 576 and 577.	Tyrosine	190-193	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	22-25
19116446-3	2008	LPA induced COX-2 expression in a dose-dependent manner, and pretreatment of the cells with pharmacological inhibitors of Gi (pertussis toxin), Src (PP2), EGF receptor (EGFR) (AG1478), ERK (PD98059) significantly inhibited LPA- induced COX-2 expression.	lysophosphatidic acid	0-3	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	149-152
18794807-4	2008	As detected by MTT proliferation assay, propidium iodide and annexin V staining, a combination of 5-FU+Src kinase inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) reflected the chemotherapeutic sensitivity and restored the 5-FU-induced apoptosis in 5-FU-resistant cells.	AG 1879	129-192	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	124-127
18794807-4	2008	As detected by MTT proliferation assay, propidium iodide and annexin V staining, a combination of 5-FU+Src kinase inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) reflected the chemotherapeutic sensitivity and restored the 5-FU-induced apoptosis in 5-FU-resistant cells.	Fluorouracil	254-258	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	124-127
18794807-4	2008	As detected by MTT proliferation assay, propidium iodide and annexin V staining, a combination of 5-FU+Src kinase inhibitor PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) reflected the chemotherapeutic sensitivity and restored the 5-FU-induced apoptosis in 5-FU-resistant cells.	Fluorouracil	254-258	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	124-127
18794807-6	2008	Western blotting and RT-PCR analysis revealed that the expression of thymidylate synthase (TS) was higher in 5-FU-resistant cells, however, decreased significantly after pretreatment with PP2.	Fluorouracil	109-113	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	188-191
18794807-7	2008	Furthermore, the combination of 5-FU+PP2 decreased the 5-FU-induced activation of epidermal growth factor receptor (EGFR)-AKT pathway.	Fluorouracil	55-59	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	37-40
18786925-4	2008	In addition, Src family kinase (SFK)-specific inhibitor, PP2, inhibited SNAP- and 8-Br-cGMP-evoked motility implicating the involvement of SFKs downstream of NO/cGMP.	8-bromoguanosino-3',5'-cyclic monophosphorothioate	82-91	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	57-60
18786925-4	2008	In addition, Src family kinase (SFK)-specific inhibitor, PP2, inhibited SNAP- and 8-Br-cGMP-evoked motility implicating the involvement of SFKs downstream of NO/cGMP.	Cyclic GMP	87-91	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	57-60
18757826-6	2008	Inhibition of FAK/Src activity by PP2 {4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine} abolished the phosphorylation of AKT, TSC2, and S6 kinase, as well as the hypertrophy of NRVMs induced by Shp2 depletion.	AG 1879	39-102	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	34-37
18596211-9	2008	Src tyrosine phosphorylation following BzATP stimulation was reduced by KN-62, TAT-P2X(7) peptide, and by the Src tyrosine inhibitor PP2 and these compounds prevented both large-conductance Panx1 currents and membrane permeabilization.	Tyrosine	4-12	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	133-136
18596211-9	2008	Src tyrosine phosphorylation following BzATP stimulation was reduced by KN-62, TAT-P2X(7) peptide, and by the Src tyrosine inhibitor PP2 and these compounds prevented both large-conductance Panx1 currents and membrane permeabilization.	BzATP	39-44	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	133-136
18596211-9	2008	Src tyrosine phosphorylation following BzATP stimulation was reduced by KN-62, TAT-P2X(7) peptide, and by the Src tyrosine inhibitor PP2 and these compounds prevented both large-conductance Panx1 currents and membrane permeabilization.	Tyrosine	114-122	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	133-136
18550847-7	2008	Addition of low concentrations of 8-bromo-cGMP, however, corrected the defective stable adhesion of Lyn-knockout platelets or PP2-treated platelets on VWF.	8-bromocyclic GMP	34-46	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	126-129
18423982-5	2008	The depletion of membrane-bound beta-catenin coincided with enhanced cell migration and invasion, and this acidic pHe-increased cell migration and invasion was prevented by PP2.	Phenylalanine	114-117	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	173-176
18506685-4	2008	In our study, we showed that LPA induced sequential events of intercellular junction dispersal and "half-junction" formation in ovarian cancer SKOV3 cells and that Src-family kinases were involved in both processes, since the effects were abolished by the selective tyrosine kinase inhibitor PP2.	lysophosphatidic acid	29-32	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	292-295
18587263-9	2008	The inhibitory effects of PP2, cytochalasin D or phalloidin on CD98-stimulated cell adhesion were diminished by pretreatment of cells with Mn2+, which is shown to induce conformational change of integrins.	Manganese(2+)	139-143	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	26-29
18796247-6	2008	Docetaxel induced the decrease in the activity of protein phosphatase 1 (PP1) and increase in the activity of PP2 subgroups, while paclitaxel induced the increase in the activity of PP1 and decrease in the activity of PP2 subgroups.	Docetaxel	0-9	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	110-113
18796247-6	2008	Docetaxel induced the decrease in the activity of protein phosphatase 1 (PP1) and increase in the activity of PP2 subgroups, while paclitaxel induced the increase in the activity of PP1 and decrease in the activity of PP2 subgroups.	Paclitaxel	131-141	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	218-221
18550772-6	2008	Both E2-induced STAT5b tyrosine phosphorylation and STAT5-mediated transcription were also inhibited by the ER antagonist ICI 182,780 and the c-Src inhibitor PP2, indicating additional requirements for the ER and c-Src kinase activity.	Tyrosine	23-31	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	158-161
18463161-7	2008	Treatment of HT29 cells with the Src inhibitor PP2, expression of a kinase-inactive form of c-Src, and c-Src depletion by small interfering RNA (siRNA) reduce both ROS generation and the levels of active Rac1.	Reactive Oxygen Species	164-167	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	47-50
17996917-7	2008	Furthermore, fluoride activated SFKs, which was abolished by the SFK-inhibitor PP2.	Fluorides	13-21	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	79-82
18385290-11	2008	The Src inhibitor PP2 blocked pilocarpine-induced ERK activation and EGF receptor phosphorylation, without affecting ERK activation by carbachol.	Pilocarpine	30-41	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	18-21
18622047-4	2008	The loss in countering capacity of leptin on the ethanol-induced cytotoxicity was attained with cyclooxygenase inhibitor, indomethacin and nitric oxide synthase (cNOS) inhibitor, L-NAME, as well as PP2, an inhibitor of Src kinase.	Ethanol	49-56	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	198-201
18622047-5	2008	Indomethacin caused the inhibition in PGE(2) generation, pretreatment with L-NAME led to the inhibition in NO production, whereas PP2 exerted the inhibitory effect on leptin-induced changes in NO, arachidonic acid and PGE(2).	Arachidonic Acid	197-213	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	130-133
18622047-5	2008	Indomethacin caused the inhibition in PGE(2) generation, pretreatment with L-NAME led to the inhibition in NO production, whereas PP2 exerted the inhibitory effect on leptin-induced changes in NO, arachidonic acid and PGE(2).	Prostaglandins E	218-221	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	130-133
18371298-7	2008	Inhibition of Lck by treatment of PP2, a Lck inhibitor or siRNA targeting of Lck suppressed sphingosine-induced conformational activation and oligomerization of Bak, mitochondrial membrane potential loss, and apoptotic cell death, implying that activation of Lck is critically required for sphingosine-induced conformational activation of Bak and mitochondrial cell death.	Sphingosine	92-103	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	34-37
18340408-4	2008	The loss in countering capacity of leptin on the ethanol-induced cytotoxicity was attained with cyclooxygenase inhibitor, indomethacin and nitric oxide synthase (cNOS) inhibitor, L-NAME, as well as PP2, an inhibitor of Src kinase.	Ethanol	49-56	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	198-201
18340408-5	2008	Indomethacin, while not affecting leptin-induced arachidonic acid release, caused the inhibition in PGE2 generation, pretreatment with L-NAME led to the inhibition in NO production, whereas PP2 exerted the inhibitory effect on leptin-induced changes in NO, arachidonic acid, and PGE2.	Indomethacin	0-12	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	190-193
18340408-5	2008	Indomethacin, while not affecting leptin-induced arachidonic acid release, caused the inhibition in PGE2 generation, pretreatment with L-NAME led to the inhibition in NO production, whereas PP2 exerted the inhibitory effect on leptin-induced changes in NO, arachidonic acid, and PGE2.	Arachidonic Acid	257-273	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	190-193
18340408-5	2008	Indomethacin, while not affecting leptin-induced arachidonic acid release, caused the inhibition in PGE2 generation, pretreatment with L-NAME led to the inhibition in NO production, whereas PP2 exerted the inhibitory effect on leptin-induced changes in NO, arachidonic acid, and PGE2.	Dinoprostone	279-283	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	190-193
18340408-7	2008	Further, leptin suppression of ethanol cytotoxicity was reflected in the increased Akt and cNOS phosphorylation that was sensitive to PP2.	Ethanol	31-38	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	134-137
18211801-4	2008	We found that GIT1 was abundantly expressed in platelets and underwent tyrosine phosphorylation downstream of integrin alpha(IIb)beta(3), which was inhibited by the Src kinase inhibitor PP2.	Tyrosine	71-79	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	186-189
18490175-8	2008	The activation was significantly blocked by PP2, an inhibitor of Src family tyrosine kinase and rottlerin, an inhibitor of PKC delta (p<0.01).	rottlerin	96-105	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	44-47
18326860-6	2008	Two SRC family PTK (SFK)-selective inhibitors, PP2 and SU6656, blocked LPS-induced increments in tyrosine phosphorylation of VE-cadherin and p120(ctn) and paracellular permeability.	Tyrosine	97-105	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	47-50
18326860-6	2008	Two SRC family PTK (SFK)-selective inhibitors, PP2 and SU6656, blocked LPS-induced increments in tyrosine phosphorylation of VE-cadherin and p120(ctn) and paracellular permeability.	trans-crotonin	146-149	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	47-50
17906699-7	2008	Inhibition of either Pyk2 or Src kinases by lentiviral RNAi or pharmacological inhibition with PP2, respectively, attenuated basal and neuropeptide-elicited survival and proliferation of SCLC cells in liquid culture and in soft agar.	Agar	228-232	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	95-98
18078709-2	2008	In two human pancreatic cancer cell lines, PK-9 and MIA PaCa-2, we found that a selective Src protein tyrosine kinase inhibitor, PP2, inhibited gemcitabine-induced cell growth suppression.	gemcitabine	144-155	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	129-132
18056483-6	2008	The SFK inhibitor, PP2, strongly reduced the global level of tyrosine phosphorylations, inhibited cell proliferation, and induced apoptosis in patient samples without affecting normal granulomonocytic colony forming units.	Tyrosine	61-69	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	19-22
17996917-8	2008	PP2 substantially inhibited the increased levels of IL-8, and partially reduced the fluoride-induced activation of ERK1/2, p38 and JNK1/2.	Fluorides	84-92	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
17996917-9	2008	Fluoride exposure also led to a phosphorylation of the EGFR, that was partially inhibited by PP2.	Fluorides	0-8	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	93-96
17899168-5	2008	Thrombin plus hyposmolarity increased src and EGFR phosphorylation, whose blockade by PP2 and AG1478, decreased by 30-50%, respectively, the thrombin effects on hyposmotic taurine efflux, ICI-swell and RVD.	Taurine	172-179	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	86-89
18068154-8	2008	However, PAR-mediated thromboxane generation (an event mediated by ERK) was potentiated by OXSI-2 whereas PP2 and piceatannol brought thromboxane to basal levels.	Thromboxanes	134-145	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	106-109
18156174-8	2008	Treatment of Src inhibitor PP2 effectively attenuated EGF-dependent activation and Tyr-529 phosphorylation of RSK2, suggesting that Src family members are the kinases that phosphorylate RSK2 at Tyr-529 in response to EGF.	Tyrosine	83-86	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	27-30
18156174-8	2008	Treatment of Src inhibitor PP2 effectively attenuated EGF-dependent activation and Tyr-529 phosphorylation of RSK2, suggesting that Src family members are the kinases that phosphorylate RSK2 at Tyr-529 in response to EGF.	Tyrosine	194-197	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	27-30
17977941-2	2008	To investigate the mechanism of modulation by Src of HCN channels, we studied the effects of a selective inhibitor of Src tyrosine kinase, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2), on HCN4 and its mutant channels expressed in HEK 293 cells by using a whole cell patch-clamp technique.	AG 1879	139-202	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	204-207
17875324-3	2008	Here we show that the pyrazolo pyrimidine compound PP2, a selective inhibitor of Src family kinases (SFK), can inhibit LPS-induced TNF production as well as a number of other inflammatory cytokines.	pyrazolo pyrimidine	22-41	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	51-54
18209475-4	2008	RESULTS: 5-HT accumulation in platelets pre-treated with reserpine, which prevents the neurotransmitter transport into the dense granules, decreased upon cellular exposure to PP2 and SU6656, two structurally unrelated inhibitors of Src-kinases.	Reserpine	57-66	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	175-178
18209475-7	2008	The Tyr-phosphorylation degree of SERT immunoprecipitated from membrane extracts decreased by platelet treatment with SU6656 or PP2, and enhanced upon pervanadate treatment.	Tyrosine	4-7	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	128-131
18257749-2	2008	2 Inhibitors of this kinase (PP2 and Src Inhibitor II) decreased ( approximately 50-75%) noradrenaline- (NA) and phorbol myristate acetate-mediated receptor phosphorylation.	Norepinephrine	89-102	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	29-32
18257749-2	2008	2 Inhibitors of this kinase (PP2 and Src Inhibitor II) decreased ( approximately 50-75%) noradrenaline- (NA) and phorbol myristate acetate-mediated receptor phosphorylation.	Tetradecanoylphorbol Acetate	113-138	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	29-32
18257749-7	2008	4 Cell pretreatment with PP2 amplified the increase in intracellular-free calcium observed with NA, in the basal state and after the stimulation (desensitization) induced by ET-1.	Calcium	74-81	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	25-28
18209475-9	2008	Platelet treatment with PP2 or SU6656 also caused a decrease in the imipramine binding to platelets.	Imipramine	68-78	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	24-27
17786281-3	2007	These effects were blocked by a tyrosine kinase inhibitor (PP2) or Src small interfering RNA (siRNA), indicating that Src was involved in the PMA-induced activation of Cas/Crk/Rac1 signaling pathway.	Tetradecanoylphorbol Acetate	142-145	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	59-62
17942635-5	2007	Whole cell calcium currents were reduced by 58 + 5% by the Src kinase inhibitor PP2 and 64 + 6% by peroxynitrite.	Calcium	11-18	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	80-83
17942635-10	2007	The inhibitory effects of PP2 and peroxynitrite on calcium currents were significantly reduced in the double mutant Y(1837-2134F).	Calcium	51-58	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	26-29
17643958-2	2007	In this study, we demonstrated that mAChR stimulation also induced a time-dependent increase in the tyrosine phosphorylation of proline-rich tyrosine kinase 2 (Pyk2), which was prevented by pretreatment of thyroid epithelial cells with the specific Src-family tyrosine kinase inhibitor PP2.	Tyrosine	100-108	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	286-289
17786281-8	2007	We demonstrated that PMA induced phosphorylation of Crk, and this phosphorylation was blocked by PP2 or Src siRNA.	Tetradecanoylphorbol Acetate	21-24	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	97-100
17676818-8	2007	Tyr kinase reactions were also performed in the presence of a well-defined small-molecule inhibitor, 4-amino-5-(4-chlorophenyl)-7- (tert-butyl)pyrazolo[3,4-d]pyrimidine (PP2).	4-amino-5-(4-chlorophenyl)-7- (tert-butyl)pyrazolo[3,4-d]pyrimidine	101-168	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	170-173
17676818-9	2007	Based on the dependency of Tyr oxidation signal on inhibitor concentration, IC50 value, half-maximal inhibition of the inhibitor, was estimated as 5 nM for PP2.	Tyrosine	27-30	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	156-159
17329403-4	2007	ANG II stimulated an increase in tyrosine phosphorylation of sequence homology of collagen (Shc; 15 min) that was prevented when PAECs were pretreated with 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo-[3,4-d]pyrimidine (PP2), a Src inhibitor.	Tyrosine	33-41	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	222-225
17559259-1	2007	The absorption and fluorescence properties of a polyphenylethynylene based conjugated polyelectrolyte with sulfonate solubilizing groups (PP2) are shown to change dramatically with solution conditions because of the equilibrium between unaggregated and aggregated forms of the polymer.	polyphenylethynylene	48-68	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	138-141
17559259-1	2007	The absorption and fluorescence properties of a polyphenylethynylene based conjugated polyelectrolyte with sulfonate solubilizing groups (PP2) are shown to change dramatically with solution conditions because of the equilibrium between unaggregated and aggregated forms of the polymer.	sulfonate	107-116	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	138-141
17559259-1	2007	The absorption and fluorescence properties of a polyphenylethynylene based conjugated polyelectrolyte with sulfonate solubilizing groups (PP2) are shown to change dramatically with solution conditions because of the equilibrium between unaggregated and aggregated forms of the polymer.	Polymers	277-284	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	138-141
17559259-2	2007	The fluorescence of PP2 is strongly quenched on addition of counterions such as Na+, K+, Li+, and TBA+, an effect which arises from the creation of salt stabilized aggregates.	tba+	98-102	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	20-23
17575268-7	2007	Using specific Src (PP2), JNK1/2 (SB600125), or p38 (SB203580) inhibitors, we determined that alcohol treatment alone induced and together with LPS, augmented the DNA-binding capacity of the specificity protein-1 (Sp-1) and AP-1 transcription factors involved in IL-10 production via Src-mediated activation of p38 MAPK and JNK, respectively.	Alcohols	94-101	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	20-23
17617176-3	2007	In this work, a specific catalytic subunit of protein phosphatase 2A (PP2Ac-2) has been identified as a component of the signalling pathway that represses responses to ABA.	Abscisic Acid	168-171	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	70-77
17617176-4	2007	A loss-of-function pp2ac-2 mutant is hypersensitive to ABA.	Abscisic Acid	55-58	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	19-26
17617176-5	2007	Moreover, pp2ac-2 plants have altered responses in developmental and environmental processes that are mediated by ABA, such as primary and lateral root development, seed germination and responses to drought and high salt and sugar stresses.	Abscisic Acid	114-117	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	10-17
17617176-5	2007	Moreover, pp2ac-2 plants have altered responses in developmental and environmental processes that are mediated by ABA, such as primary and lateral root development, seed germination and responses to drought and high salt and sugar stresses.	Salts	216-220	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	10-17
17617176-5	2007	Moreover, pp2ac-2 plants have altered responses in developmental and environmental processes that are mediated by ABA, such as primary and lateral root development, seed germination and responses to drought and high salt and sugar stresses.	Sugars	225-230	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	10-17
17617176-6	2007	Conversely, transgenic plants overexpressing PP2Ac-2 are less sensitive to ABA than wild type, a phenotype that is manifested in all the above-mentioned physiological processes.	Abscisic Acid	75-78	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	45-52
17617176-7	2007	DNA microarray hybridization experiments reveal that PP2Ac-2 is negatively involved in ABA responses through regulation of ABA-dependent gene expression.	Abscisic Acid	87-90	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	53-60
17617176-7	2007	DNA microarray hybridization experiments reveal that PP2Ac-2 is negatively involved in ABA responses through regulation of ABA-dependent gene expression.	Abscisic Acid	123-126	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	53-60
17617176-8	2007	Moreover, the results obtained indicate that ABA antagonistically regulates PP2Ac-2 expression and PP2Ac-2 activity thus allowing plant sensitivity to the hormone to be reset after induction.	Abscisic Acid	45-48	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	76-83
17617176-8	2007	Moreover, the results obtained indicate that ABA antagonistically regulates PP2Ac-2 expression and PP2Ac-2 activity thus allowing plant sensitivity to the hormone to be reset after induction.	Abscisic Acid	45-48	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	99-106
17617176-9	2007	Phenotypic, genetic and gene expression data strongly suggest that PP2Ac-2 is a negative regulator of the ABA pathway.	Abscisic Acid	106-109	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	67-74
17329403-4	2007	ANG II stimulated an increase in tyrosine phosphorylation of sequence homology of collagen (Shc; 15 min) that was prevented when PAECs were pretreated with 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo-[3,4-d]pyrimidine (PP2), a Src inhibitor.	AG 1879	156-220	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	222-225
17329403-6	2007	The ANG II-dependent increase in Ras GTP binding was prevented when PAECs were pretreated with the AT(2) antagonist PD-123319 or with PP2 or were transfected with Src DN cDNA.	Guanosine Triphosphate	37-40	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	134-137
17251321-3	2007	Inhibition of tyrosine phosphorylation with the tyrosine kinase inhibitors genistein or PP2 significantly reduced the increase in [Ca(2+)](i) observed after H(2)O(2) or TNFalpha treatment in TRPM2-expressing cells, suggesting that phosphorylation is important in TRPM2 activation.	Tyrosine	14-22	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	88-91
17215324-10	2007	PP2 also blocked strain-induced phosphorylation of FAK-Tyr(576) and ERK-Thr(202)/Tyr(204) but not FAK-Tyr(397).	Tyrosine	55-58	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
17215324-10	2007	PP2 also blocked strain-induced phosphorylation of FAK-Tyr(576) and ERK-Thr(202)/Tyr(204) but not FAK-Tyr(397).	Threonine	72-75	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
17215324-10	2007	PP2 also blocked strain-induced phosphorylation of FAK-Tyr(576) and ERK-Thr(202)/Tyr(204) but not FAK-Tyr(397).	Tyrosine	81-84	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
17215324-10	2007	PP2 also blocked strain-induced phosphorylation of FAK-Tyr(576) and ERK-Thr(202)/Tyr(204) but not FAK-Tyr(397).	Tyrosine	81-84	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
17186496-3	2007	A sequential analysis of the obestatin transmembrane signaling pathway showed that the ERK 1/2 activity is partially blocked after preincubation of the cells with pertussis toxin (PTX), as well as by wortmannin (an inhibitor of PI3K), claphostin C (an inhibitor of PKC), and PP2 (which inhibits the non receptor tyrosine kinase Src).	Wortmannin	200-210	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	275-278
17432977-10	2007	Treatment of MYL-R cells with various reagents known to have anti-leukemic activity revealed that zoledronic acid and the farnesyl transferase inhibitor (SCH 66336) showed strong synergism with imatinib; interferon alpha, PP2, CGP76030, and FK228 (depsipeptide) showed synergism; whereas soluble TRAIL and As2O3 showed additivity or antagonism, and 17-AAG and radicicol showed antagonism.	Zoledronic Acid	98-113	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	222-225
17432977-10	2007	Treatment of MYL-R cells with various reagents known to have anti-leukemic activity revealed that zoledronic acid and the farnesyl transferase inhibitor (SCH 66336) showed strong synergism with imatinib; interferon alpha, PP2, CGP76030, and FK228 (depsipeptide) showed synergism; whereas soluble TRAIL and As2O3 showed additivity or antagonism, and 17-AAG and radicicol showed antagonism.	lonafarnib	154-163	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	222-225
17432977-11	2007	Treatment with either PP2 or zoledronic acid induced greater growth-reduction in MYL-R than MYL.	myl-r	81-86	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	22-25
17386790-8	2007	Tyrosine kinase reactions were also performed in the presence of a well-defined inhibitor, 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2), and its negative control molecule, 4-amino-7-phenylpyrazol[3,4-d] pyrimidine (PP3), which had no inhibition effect.	AG 1879	91-155	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	157-160
17675065-8	2007	Interestingly, chelerythrine, a PKC inhibitor, and PP2, a Src kinase family inhibitor, reduced G6PD activity (0.29 +/- 0.04 nM x min x mg protein) by 50% and 51% and these inhibitors also decreased myocardial superoxide by 99% and 79%, respectively.	Superoxides	209-219	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	51-54
17251460-8	2007	Consistent with the effects on epithelial migration, these inhibitors, as well as the Src kinase inhibitor (PP2), retarded LPA-induced activation of EGFR and its downstream effectors ERK and AKT in THCE cells.	lysophosphatidic acid	123-126	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	108-111
17251460-8	2007	Consistent with the effects on epithelial migration, these inhibitors, as well as the Src kinase inhibitor (PP2), retarded LPA-induced activation of EGFR and its downstream effectors ERK and AKT in THCE cells.	thce	198-202	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	108-111
17251460-11	2007	The release of HB-EGF assessed by AP activity increased significantly in response to wounding, LPA, or both, and the release of HB-EGF-AP induced by LPA was inhibited by PP2 and GM6001.	lysophosphatidic acid	149-152	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	170-173
17121804-5	2007	The chemical Src inhibitor PP2 {4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo [3,4-d]pyrimidine} and the PI 3-kinase inhibitor LY294002 each inhibited Akt phosphorylation and the colocalization of RV39 with Akt.	AG 1879	32-96	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	27-30
17244733-10	2007	The protein phosphatase PP1/PP2 inhibitors calyculin and okadaic acid increased the isotonic volume only slightly but they greatly increased the relative cell volume and blocked RVD.	Okadaic Acid	57-69	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	28-31
17169446-4	2007	The m2 receptor antagonist methoctramine or the c-Src inhibitor PP2 blocked the effect of ACh, suggesting that the augmentation was mediated by c-Src, derived from m2 receptor activation.	Acetylcholine	90-93	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	64-67
17169446-5	2007	ACh induced activation of c-Src and phosphorylation of GRK2 and the effects of ACh were blocked by methoctramine, PP2, or by uncoupling of m2 receptors from G(i3) with pertussis toxin.	Acetylcholine	0-3	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	114-117
17169446-5	2007	ACh induced activation of c-Src and phosphorylation of GRK2 and the effects of ACh were blocked by methoctramine, PP2, or by uncoupling of m2 receptors from G(i3) with pertussis toxin.	Acetylcholine	79-82	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	114-117
17223712-2	2007	A Western blotting analysis showed that such action of TCDD in MCF10A cells could effectively be suppressed by treatment with a specific inhibitor of Src family kinase, PP-2, as judged by Western blot detection of the active form of Src protein, indicating that Src kinase is directly activated by TCDD.	Polychlorinated Dibenzodioxins	55-59	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	169-173
17223712-2	2007	A Western blotting analysis showed that such action of TCDD in MCF10A cells could effectively be suppressed by treatment with a specific inhibitor of Src family kinase, PP-2, as judged by Western blot detection of the active form of Src protein, indicating that Src kinase is directly activated by TCDD.	Polychlorinated Dibenzodioxins	298-302	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	169-173
17062641-4	2006	Inhibitors of Src (PP2, SU6656) or EGFR (AG99), but not p145(met) (K252a), effectively blocked tyrosine phosphorylation of p145(met) and promoted cell death accompanied by activation of caspase-like proteases.	Tyrosine	95-103	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	19-22
16891393-8	2006	PP2 also blocked TNF-alpha-induced tyrosine phosphorylation of VE-cadherin, gamma-catenin, and p120(ctn).	Tyrosine	35-43	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
16650892-3	2006	The tyrosine phosphorylation levels of GHR and STAT5 induced by GH decreased in the presence of PP2 Src kinase inhibitor.	Tyrosine	4-12	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	96-99
17068290-6	2006	The proliferative effect of C-peptide on VSMCs was inhibited by Src short interference RNA transfection, PP2, an inhibitor of Src-kinase, LY294002, an inhibitor of PI-3 kinase, and the ERK1/2 inhibitor PD98059.	vsmcs	41-46	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	105-108
16682172-9	2006	PP2, a Src kinase inhibitor, inhibited the tyrosine phosphorylation of SHIP1 as well as its translocation to the plasma membrane.	Tyrosine	43-51	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
17010316-1	2006	Recently we demonstrated that PP2 (4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), a potent and selective inhibitor of the Src-family tyrosine kinase, markedly enhanced Ras-independent activation of Raf-1 by the combination of phorbol myristate acetate (PMA) and hydrogen peroxide (H(2)O(2)).	4-amino-5-(4-chloro-phenyl)-7-(	35-66	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	30-33
17010316-1	2006	Recently we demonstrated that PP2 (4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), a potent and selective inhibitor of the Src-family tyrosine kinase, markedly enhanced Ras-independent activation of Raf-1 by the combination of phorbol myristate acetate (PMA) and hydrogen peroxide (H(2)O(2)).	-butyl)pyrazolo[3,4-d]pyrimidine	67-99	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	30-33
17010316-1	2006	Recently we demonstrated that PP2 (4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), a potent and selective inhibitor of the Src-family tyrosine kinase, markedly enhanced Ras-independent activation of Raf-1 by the combination of phorbol myristate acetate (PMA) and hydrogen peroxide (H(2)O(2)).	Tetradecanoylphorbol Acetate	246-271	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	30-33
17010316-1	2006	Recently we demonstrated that PP2 (4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), a potent and selective inhibitor of the Src-family tyrosine kinase, markedly enhanced Ras-independent activation of Raf-1 by the combination of phorbol myristate acetate (PMA) and hydrogen peroxide (H(2)O(2)).	Tetradecanoylphorbol Acetate	273-276	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	30-33
17010316-1	2006	Recently we demonstrated that PP2 (4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), a potent and selective inhibitor of the Src-family tyrosine kinase, markedly enhanced Ras-independent activation of Raf-1 by the combination of phorbol myristate acetate (PMA) and hydrogen peroxide (H(2)O(2)).	Hydrogen Peroxide	282-299	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	30-33
17010316-1	2006	Recently we demonstrated that PP2 (4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), a potent and selective inhibitor of the Src-family tyrosine kinase, markedly enhanced Ras-independent activation of Raf-1 by the combination of phorbol myristate acetate (PMA) and hydrogen peroxide (H(2)O(2)).	Water	301-306	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	30-33
16882656-5	2006	Co-incubation of fibroblasts for 24 h with SSC or LG3 in the presence of PP2 (AG1879), a biochemical inhibitor of Src family kinases (SFKs) and focal adhesion kinase, showed a significantly decreased anti-apoptotic response.	AG 1879	78-84	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	73-76
16875784-7	2006	Preincubation of platelets with the Src kinase inhibitor PP2 (20 microM) blocked VO4-induced tyrosine phosphorylation of NOS and abolished the effects of VO4 on cGMP formation.	VO4	81-84	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	57-60
16597920-5	2006	hGH caused tyrosine phosphorylation of Janus kinase (JAK)2 and c-Src, events inhibited by the JAK2 inhibitor AG490 or the Src kinase inhibitor PP2.	Tyrosine	11-19	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	143-146
16875784-7	2006	Preincubation of platelets with the Src kinase inhibitor PP2 (20 microM) blocked VO4-induced tyrosine phosphorylation of NOS and abolished the effects of VO4 on cGMP formation.	Tyrosine	93-101	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	57-60
16875784-7	2006	Preincubation of platelets with the Src kinase inhibitor PP2 (20 microM) blocked VO4-induced tyrosine phosphorylation of NOS and abolished the effects of VO4 on cGMP formation.	VO4	154-157	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	57-60
16875784-7	2006	Preincubation of platelets with the Src kinase inhibitor PP2 (20 microM) blocked VO4-induced tyrosine phosphorylation of NOS and abolished the effects of VO4 on cGMP formation.	Cyclic GMP	161-165	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	57-60
16928856-5	2006	Intrathecal administration of the Src-family tyrosine kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) suppressed nerve injury-induced mechanical hypersensitivity but not heat and cold hypersensitivity.	AG 1879	71-134	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	136-139
16236484-6	2006	Treatment of cells with the Ca2+ chelator BAPTA-AM and inhibition of Src and PLD2 with PP2 or 1-butanol, respectively, abrogated P2Y12 receptor-mediated activation of Rap1 and PKB.	1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester	42-50	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	87-90
16998541-9	2006	Furthermore, pharmacological inhibition of Src by PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazole(3,4-d) pyrimidine) decreased PKB phosphorylation.	4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazole	55-101	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	50-53
16569213-9	2006	Ang II-stimulated phosphorylation of the p70 PDGFR-beta was blocked by the AT1 receptor antagonist, candesartan (CV 11974) and was partially inhibited by PP2 {4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine}, an Src family kinase inhibitor.	AG 1879	159-222	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	154-157
16714287-4	2006	The effect of ouabain was additive to the effect of insulin and was independent of phosphatidylinositol 3-kinase inhibitor LY294002 but was abolished in the presence of a MEK1/2 inhibitor (PD98059) or a Src inhibitor (PP2).	Ouabain	14-21	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	218-221
16714287-6	2006	Phosphorylation of ERK1/2 and GSK3alpha/beta, as well as p90rsk activity, was increased in response to ouabain in HSMC, and these responses were prevented in the presence of PD98059 and PP2.	hsmc	114-118	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	186-189
16814101-3	2006	This H2O2-induced kinase activation was significantly attenuated by a Src kinase inhibitor PP2, or by transient transfection of carboxyl-terminal Src kinase (CSK) that maintained Src in the dormant form.	Hydrogen Peroxide	5-9	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	91-94
16998541-9	2006	Furthermore, pharmacological inhibition of Src by PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazole(3,4-d) pyrimidine) decreased PKB phosphorylation.	3,4-d) pyrimidine	102-119	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	50-53
16998541-10	2006	Moreover, H2O2-induced PKB phosphorylation was associated with increased tyrosine phosphorylation of c-Src and Pyk2 in an AG1024- and PP2-inhibitable manner.	Hydrogen Peroxide	10-14	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	134-137
16799022-7	2006	Effects of PP2 on THCE cell migration were determined by Boyden chamber migration assay.	thce	18-22	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	11-14
16799022-8	2006	RESULTS: Among several inhibitors tested, PP2 blocked wound-induced EGFR phosphorylation in THCE cells.	thce	92-96	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	42-45
16799022-9	2006	PP2 at 12.5 microM effectively inhibited EGFR transactivation in response to wounding and to the phosphorylation of ERK and AKT in THCE cells and primary HCECs.	thce	131-135	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
16707113-5	2006	Inhibition of Src family kinases with PP2, but not the inactive analogue PP3, also interfered with LPA-mediated tyrosine phosphorylation and induction of CTGF.	lysophosphatidic acid	99-102	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	38-41
16707113-5	2006	Inhibition of Src family kinases with PP2, but not the inactive analogue PP3, also interfered with LPA-mediated tyrosine phosphorylation and induction of CTGF.	Tyrosine	112-120	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	38-41
16531982-8	2006	Interference with Src activity by PP2 had no effect on the morphological alterations but decreased tyrosine phosphorylation of focal adhesion proteins and almost completely prevented upregulation of CTGF.	Tyrosine	99-107	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	34-37
16157345-7	2006	Immunoblotting analysis showed that 5-HT at 10 microM increased ACAT-1 protein expression level by two-fold, and this effect was abolished completely by a 5-HT2A receptor antagonist (sarpogrelate), its major metabolite (M-1), a G protein inactivator (GDP-beta-S), a protein kinase C (PKC) inhibitor (rottlerin), a Src family inhibitor (PP2), or a mitogen-activated protein kinase (MAPK) kinase inhibitor (PD98059).	sarpogrelate	183-195	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	336-339
16513647-9	2006	In addition, Src inhibitor PP2 caused nuclear accumulation of Nrf 2 in normal and hydrogen peroxide-treated cells but had no effect on localization of mutant Nrf 2Y568A.	Hydrogen Peroxide	82-99	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	27-30
16284210-10	2006	An Src inhibitor, PP2, and the phosphatidylinositol-3-kinase inhibitor, LY-294002, blocked dopamine"s effect on ENaC.	Dopamine	91-99	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	18-21
16523241-6	2006	Interestingly dephosphorylation at Tyr577 of FAK by PP2 treatment, Src-family kinase inhibitor, induced the apoptosis by staurosporine in senescent cells but dephosphorylation at Tyr397 by downregulation of caveolin-1 was not affected.	Staurosporine	121-134	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	52-55
16410281-10	2006	Surprisingly, inhibition of SFKs by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d] pyrimidine (PP2) or herbimycin A had different effects on trophoblast differentiation.	AG 1879	36-101	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	103-106
16439036-4	2006	Activation of Akt by carbachol was antagonized by atropine and inhibited by LY294002 and PP2.	Carbachol	21-30	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	89-92
16439036-5	2006	The Src-like tyrosine kinase inhibitor, PP2, also reduced carbachol stimulation of extracellular signal-regulated kinases 1/2 and cAMP-response element binding protein in a dose-dependent manner.	Carbachol	58-67	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	40-43
16439036-5	2006	The Src-like tyrosine kinase inhibitor, PP2, also reduced carbachol stimulation of extracellular signal-regulated kinases 1/2 and cAMP-response element binding protein in a dose-dependent manner.	Cyclic AMP	130-134	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	40-43
16487511-9	2006	The indomethacin-induced inhibition of C6 cells proliferation was abrogated by the use of the c-Src inhibitor, PP2 and the MEK inhibitor, PD 098059, suggesting COX-independent mechanisms.	Indomethacin	4-16	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	111-114
16322069-9	2006	In addition, results from Western blots, ERK1/2 and Akt, which are downstream effectors of Flk-1/KDR, were also activated by LPC, and this was inhibited by SU1498, VTKi, herbimycin A, PP2, and KI Src transfection in HUVECs.	herbimycin	170-182	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	184-187
16322069-9	2006	In addition, results from Western blots, ERK1/2 and Akt, which are downstream effectors of Flk-1/KDR, were also activated by LPC, and this was inhibited by SU1498, VTKi, herbimycin A, PP2, and KI Src transfection in HUVECs.	SU 1498	156-162	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	184-187
16267051-8	2005	A concomitant treatment with beta-cyclodextrin and a Src family kinase inhibitor, PP2, specifically blocked axon outgrowth but not dendrite outgrowth (both of which were enhanced by beta-cyclodextrin) in hippocampal neurons, suggesting that axon outgrowth modulated by cholesterol is induced in a Fyn-dependent manner.	betadex	29-46	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	82-85
16477014-7	2006	IL-1beta-mediated hyperpolarization is blocked by PP2, the selective inhibitor of the protein tyrosine kinase Src, which is known to be activated by ceramide.	Ceramides	149-157	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	50-53
16267051-8	2005	A concomitant treatment with beta-cyclodextrin and a Src family kinase inhibitor, PP2, specifically blocked axon outgrowth but not dendrite outgrowth (both of which were enhanced by beta-cyclodextrin) in hippocampal neurons, suggesting that axon outgrowth modulated by cholesterol is induced in a Fyn-dependent manner.	betadex	182-199	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	82-85
16267051-8	2005	A concomitant treatment with beta-cyclodextrin and a Src family kinase inhibitor, PP2, specifically blocked axon outgrowth but not dendrite outgrowth (both of which were enhanced by beta-cyclodextrin) in hippocampal neurons, suggesting that axon outgrowth modulated by cholesterol is induced in a Fyn-dependent manner.	Cholesterol	269-280	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	82-85
15870699-4	2005	Activity of Src family kinase correlated well with metastatic potential, and a Src family kinase inhibitor, PP2, not only abolished tyrosine phosphorylation of paxillin but also impaired the motility of high-metastatic sublines.	Tyrosine	132-140	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	108-111
16257269-6	2005	In addition, pretreatment of ECs with AG-490, an inhibitor of JAK2, prevented nuclear fragmentation, whereas inhibitors of Jun kinase (SP 600125), MAP kinase (PD 98059), Src kinase (PP2) or PI-3 kinase (wortmannin) were without effect.	alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide	38-44	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	182-185
16139998-4	2005	Treatment with the selective Src family inhibitor pyrazolopyrimidine PP-2 prevented STAT5 phosphorylation at Tyr-694, nuclear translocation of STAT5 and the STAT5-DNA complex formation.	1H-pyrazolo[4,3-d]pyrimidine	50-68	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	69-73
16139998-4	2005	Treatment with the selective Src family inhibitor pyrazolopyrimidine PP-2 prevented STAT5 phosphorylation at Tyr-694, nuclear translocation of STAT5 and the STAT5-DNA complex formation.	Tyrosine	109-112	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	69-73
16140770-6	2005	However, endoglycosidase H (endoH) digestion of the viral envelope (E) glycoprotein revealed that the acquisition of endoH-resistant glycans by E, but not endogenous major histocompatibility complex class I, was reduced in PP2-treated cells, demonstrating that E specifically does not traffic beyond the endoplasmic reticulum in the absence of SFK activity.	Polysaccharides	133-140	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	223-226
15944285-6	2005	The recruitment and tyrosine phosphorylation of most proteins were abolished when T cells were stimulated in the presence of the SFK inhibitor PP2.	Tyrosine	20-28	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	143-146
16014719-7	2005	Tyrosine phosphorylation of tau was inhibited by PP2 (4-amino-5-(4-chlorophenyl-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), which is known to inhibit Src-family kinases and c-Abl.	Tyrosine	0-8	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	49-52
16014719-7	2005	Tyrosine phosphorylation of tau was inhibited by PP2 (4-amino-5-(4-chlorophenyl-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), which is known to inhibit Src-family kinases and c-Abl.	AG 1879	54-116	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	49-52
15923189-6	2005	PP2 (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine) inhibited association of GIT1 with ERK1/2, and their co-localization in focal adhesions was dramatically decreased in SYF-/- cells.	AG 1879	5-68	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	0-3
15985706-5	2005	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.	Isoproterenol	41-54	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	87-90
15689414-8	2005	The stimulatory effects of isoproterenol and cAMP on ERK phosphorylation were not reduced by the PKA inhibitor H-89, whereas the Src family inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidase (PP2) and transfection of a dominant-negative Src construct diminished isoproterenol-induced ERK activation.	Isoproterenol	27-40	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	215-218
15689414-8	2005	The stimulatory effects of isoproterenol and cAMP on ERK phosphorylation were not reduced by the PKA inhibitor H-89, whereas the Src family inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidase (PP2) and transfection of a dominant-negative Src construct diminished isoproterenol-induced ERK activation.	Cyclic AMP	45-49	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	215-218
15985706-5	2005	The gastric mucin secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR autophosphorylation, but not by ERK inhibitor, PD98059.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	224-231	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	87-90
15546949-6	2005	Costimulation of G(i) plus G(z) pathways also caused thromboxane generation that was dependent on outside-in signaling and was inhibited by PP2, a Src family tyrosine kinase inhibitor.	Thromboxanes	53-64	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	140-143
15774483-6	2005	Pretreatment of HPAECs with the Src kinase inhibitor PP2 (1 mum) or transient expression of a dominant-negative mutant of Src attenuated hyperoxia-induced tyrosine phosphorylation of Src and ROS production.	Tyrosine	155-163	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	53-56
15774483-6	2005	Pretreatment of HPAECs with the Src kinase inhibitor PP2 (1 mum) or transient expression of a dominant-negative mutant of Src attenuated hyperoxia-induced tyrosine phosphorylation of Src and ROS production.	Reactive Oxygen Species	191-194	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	53-56
15774483-7	2005	Furthermore, exposure of cells to hyperoxia enhanced tyrosine phosphorylation of p47(phox) and its translocation to cell peripheries that were attenuated by PP2.	Tyrosine	53-61	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	157-160
15799708-6	2005	Here we focus on a hydroxyl-substituted analog (hydroxy-PP) of the known Src-family kinase inhibitor PP2 because it induced cell-specific morphological features distinct from all known kinase inhibitors in the collection.	Hydroxyl Radical	19-27	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	101-104
15799708-6	2005	Here we focus on a hydroxyl-substituted analog (hydroxy-PP) of the known Src-family kinase inhibitor PP2 because it induced cell-specific morphological features distinct from all known kinase inhibitors in the collection.	hydroxy-pp	48-58	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	101-104
15772290-4	2005	Endothelin-1-induced cell growth was blocked by the pharmacological Src antagonist 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) but not by the inactive analog 4-amino-7-phenylpyrazol[3,4-d]pyrimidine.	AG 1879	83-146	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	148-151
15821021-4	2005	Pretreatment with the Src kinase inhibitors 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyriimidine (PP2) or geldanamycin or the PKA inhibitor Rp-cAMPS only partly inhibited isoproterenol- or PGE(1)-induced actin depolymerization.	4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyriimidine	44-108	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	110-113
15748889-7	2005	Podosome assembly was dependent on both PKA and tyrosine kinase activities because their formation was impaired after treatment with specific inhibitors [myristoylated PKI (mPKI) or PP2, respectively] previous to ACTH/8-Br-cAMP stimulation.	8-Bromo Cyclic Adenosine Monophosphate	218-227	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	182-185
15389641-8	2005	CCh also induced association of FAK with the EGFr and FAK phosphorylation was attenuated by an EGFr inhibitor, tyrphostin AG1478, and an inhibitor of Src family kinases, PP2.	Carbachol	0-3	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	170-173
15632127-6	2005	Interestingly, PP2, a specific Src-like kinase inhibitor, blocked the tyrosine phosphorylation of Src, Fyn, and Lyn and IGF-I-stimulated Akt activation, yet had no significant effects on caspase-3 activation or progenitor survival.	Tyrosine	70-78	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	15-18
15574683-7	2005	The data using the Src inhibitor PP2 [4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine] resemble those found when using AG-1478 in either cell type.	AG 1879	38-101	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	33-36
15574683-7	2005	The data using the Src inhibitor PP2 [4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine] resemble those found when using AG-1478 in either cell type.	RTKI cpd	135-142	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	33-36
15191880-10	2004	Tyrosine phosphorylation of paxillin was reduced by HGF and was sensitive to the Src kinase inhibitor PP2.	Tyrosine	0-8	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	102-105
15342783-5	2004	In contrast, tyrosine phosphorylation of villin and villin-induced cell migration was significantly inhibited by the src kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) as well as by overexpression of a dominant negative mutant of c-src.	Tyrosine	13-21	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	203-206
15342783-5	2004	In contrast, tyrosine phosphorylation of villin and villin-induced cell migration was significantly inhibited by the src kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) as well as by overexpression of a dominant negative mutant of c-src.	AG 1879	138-201	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	203-206
15652529-5	2005	BRL37344 treatment also increased choroidal endothelial cell invasion by 103% above control values; the invasion response was inhibited by PP2 (Src inhibitor), LY294002 (PI3K inhibitor), Akt inhibitor (Akt-I), and matrix metalloproteinase 2/9 inhibitor (MMP-I).	BRL 37344	0-8	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	139-142
15471856-7	2004	Finally, we show that inhibition of tyrosine phosphorylation by using the Src-family tyrosine kinase inhibitor PP2 resulted in enhanced release of MHC-I heavy chains from the cell surface of activated T cells and a slight down-regulation of cell surface W6/32-reactive molecules.	Tyrosine	36-44	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	111-114
15519496-5	2004	I-BOP-induced BrdU uptake was significantly blocked by two non-selective tyrosine kinase inhibitors, genistein and herbimycin A, or a Src family tyrosine kinase inhibitor, PP2, but not by an inhibitor of epidermal growth factor (EGF) receptor-associated tyrosine kinase, AG1478.	7-(3-(3-hydroxy-4-(4'-iodophenoxy)-1-butenyl)-7-oxabicyclo(2.2.1)heptan-2-yl)-5-heptenoic acid	0-5	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	172-175
15369766-8	2004	GM6001, a matrix metalloproteinase inhibitor, and PP2, a Src family protein kinase inhibitor, suppressed 15-d-PGJ2- and TZDs-induced phosphorylation of EGF-R and PDGFbeta-R as well as activation of ERK1/2 and Akt.	15-deoxy-delta(12,14)-prostaglandin J2	105-114	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	50-53
15369766-8	2004	GM6001, a matrix metalloproteinase inhibitor, and PP2, a Src family protein kinase inhibitor, suppressed 15-d-PGJ2- and TZDs-induced phosphorylation of EGF-R and PDGFbeta-R as well as activation of ERK1/2 and Akt.	Thiazolidinediones	120-124	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	50-53
15381832-5	2004	The gastric mucosal phospholipid secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR phosphorylation, but not by ERK inhibitor, PD98059.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	235-242	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	102-105
15240896-5	2004	However, IL-8 induction was most efficiently inhibited by the Src family kinase (SFK) inhibitor, PP2, suggesting a crucial role of SFKs in regulating silica-induced IL-8 release from A549 cells.	Silicon Dioxide	150-156	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	97-100
15240896-8	2004	Moreover, PP2 inhibited silica-induced phospho-ERK1/2 to near-control levels, whereas phospho-p38 was not significantly reduced by the SFK inhibitor.	Silicon Dioxide	24-30	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	10-13
15381832-5	2004	The gastric mucosal phospholipid secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR phosphorylation, but not by ERK inhibitor, PD98059.	Phospholipids	20-32	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	102-105
15381832-5	2004	The gastric mucosal phospholipid secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR phosphorylation, but not by ERK inhibitor, PD98059.	Isoproterenol	56-69	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	102-105
15084474-3	2004	Capsaicin-induced currents in identified colonic dorsal root ganglion neurons were blocked by the c-Src kinase inhibitor PP2 and enhanced by the tyrosine phosphatase inhibitor sodium orthovandate.	Capsaicin	0-9	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	121-124
15184865-1	2004	We have recently demonstrated that the pyrazolopyrimidines PP1 and PP2 and the 4-anilinoquinazoline ZD6474 display a strong inhibitory activity (IC(50)< or =100 nM) towards constitutively active oncogenic RET kinases.	pyrazolopyrimidines	39-58	neuropeptide Y receptor Y6 (pseudogene)	Homo sapiens	67-70